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1. Introduction 
 
1.1 General introduction 
The immune system is a fascinating and precious defence mechanism. It is essential 
for maintaining the integrity of the human organism. Host defence mechanisms 
consist of several defence lines such as natural barriers and non-specific (innate) as 
well as specific (adaptive) immune responses. Natural barriers, also called physical 
and chemical barriers, are the first line of defence. Physical barriers include the skin, 
which is the toughest one to overcome for a pathogen unless it is breached for 
instance by injury or catheters. Chemical barriers come into action wherever the skin 
protection is not consistent (e.g. eye). Mucous membranes are protected by secreted 
anti-microbial immunoglobulins or lysozyme which can be found in tears or saliva. 
Each region of the body has its own strategy to contributing to host defence against 
infections. Mucus and cilia located in nose and throat prevent pathogens from 
entering these open cavities by provoking coughing or sneezing. The acidic pH in the 
gastro-intestinal tract is an inhospitable environment for most pathogens (Janeway et 
al., 2005). The immune system is a highly differentiated and adaptable defence 
mechanism consisting of two components, the innate and the adaptive immune 
system. Recognition and differentiation between self- and foreign antigens and 
defending the body from diverse infectious invaders are the major tasks of the 
immune system. 
          The second line of defence is the innate immune system, which combats 
antigens that penetrated the first line of defence. The innate immune mechanism is 
non-specific and acts immediately on the clearance of pathogens but does not 
generate lasting protective immunity (Litman et al. 2005). Microorganisms, which we 
encounter in daily life, are detected and destroyed within minutes or hours by the 
various mechanisms of the innate immunity and only occasionally cause perceptible 
disease in a normal, healthy individual (Janeway et al., 2005). Phagocytes play a 
crucial role in the innate immune system as they have the capacity to effectively 
eliminate pathogens. Professional phagocytes are macrophages, mast cells, most 
dendritic cells (DCs) and granulocytes including neutrophils. These early team-
players of the immune system eliminate antigens by breaking them down with e. g. 
digestive enzymes in their lysosomes. Macrophages are, like neutrophils, 
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professional phagocytes that have the capacity to attract other cells such as T cells 
from the blood to the site of infection by the release of chemoattractive cytokines and 
thus are part of the adaptive immunity. The complement system with its classic, 
lectin, and alternative pathways is an early warning mechanism for pathogen 
detection and lysis. Complement can attach to the bacterial surface, which promotes 
phagocytosis and is a phenomenon called opsonization. Only if an infectious 
organism can breach these early lines of defence will an adaptive immune response 
ensue (Janeway et al., 2005). 
The third line of defence is the adaptive immune system. The cells of the 
adaptive immune system are the antigen-specific B-cell and T-cell lymphocytes. 
Adaptive immunity is triggered in vertebrates when a pathogen evades the innate 
immune system and generates a threshold level of antigen (Janeway et al., 2005). As 
soon as the innate immune system signals the presence of danger to the T cells of 
the adaptive immune system, T cells get involved with the B cells that have the ability 
to rearrange genes of the immunoglobulin family, permitting the creation of a large 
diversity of antigen specific clones and immunological memory (Gourley et al., 2004). 
The adaptive immune system then activates antigen-specific lymphocytes to 
proliferate and to differentiate into effector and memory cells that eliminate 
pathogens. Memory cells can prevent recurrence of disease caused by the same 
microorganism. Yet this highly sophisticated and potent adaptive immune system, 
which is a well-organized orchestra, needs to be conducted, instructed and regulated 
by antigen presenting cells (APCs).  
  
 
1.2 Antigen-presenting cells 
Phagocytes include professional APCs, which are dendritic cells (DCs) as well as 
macrophages and B cells. Bone-marrow (BM)-derived APCs are distributed in 
different compartments such as peripheral blood, lymphatic tissues, and solid organs 
to guard the host (Janeway et al., 2005). A main function of DCs is not only to engulf 
and degrade antigens intracellularly, but also to carry pathogen antigens to the 
secondary lymphatic organs, the lymph nodes and the spleen. 
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TABLE 1.1: Main characteristics of immature and mature DCs. Immature DCs 
have tremendous phagocytic activity to ingest antigens. Mature DCs have a 
phenotype that is associated with high levels of MHCI and MHCII proteins, and co-
stimulatory molecules. 
 
 Immature DCs (iDCs) Mature DCs (mDCs) 
Phagocytosis ↑↑ ↓ 
MHC molecules ↓ ↑↑ 
Co-stimulatory molecules ↓ ↑ 
 
 DCs exist in different stages of maturation which are associated with specific 
functional traits. The respective characteristics are given in Tab 1.1. Immature DCs 
have a tremendous phagocytic activity to ingest antigens either via pinocytosis or 
receptor-mediated endocytosis. Upon significant stimulation, an iDC matures to a 
mDC to activate the adaptive immune response, a process which is associated with 
loss of phagocytic activity and a high surface display of B7 molecules (CD80 and 
CD86) which is essential for T cell activation. 
 Upon antigen-mediated activation, DCs secrete cytokines that influence both 
the innate and the adaptive immune responses, which make these cells to essential 
gatekeepers that determine whether and how the immune system responds to the 
presence of infectious agents (Janeway et al., 2005). Activated DCs mature into 
highly effective APCs, a process that is associated with their loss of phagocytic 
activity. Mature DCs are generally considered to be terminally-differentiated cells, 
which have a short life span and no proliferation capacity (Shortman and Wu, 2004). 
 
 
1.3 Antigen processing and MHC-dependent antigen presentation in APCs  
Activation of the adaptive immune system by DCs is mediated by cytokine secretion 
as well as by direct presentation of antigens to T cells (Fig. 1.1). T cells circulate 
between blood and peripheral lymphoid tissue searching for their specific antigen. 
Naïve T cells are mature recirculating T cells that have not yet encountered their 
antigen. T cells consist of helper, cytotoxic and regulatory T cells. The CD4+ helper T 
cells depend on the major histocompatibility complex (MHC) class II:peptide-contact 
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to initiate and modulate receptor- and cytokine-mediated functions of the immune 
system (Kaufmann and Schaible, 2005). MHC is a membrane glycoprotein encoded 
in a cluster of genes and a molecule that displays peptide antigen to T cells. CD8+ 
cytotoxic T cells recognize endogenous antigens presented by MHC class I and 
mediate the cytotoxic immune response, as for instance the elimination of virus-
infected cells (Pamer et al., 1998). Regulatory T helper (Treg) cells suppress the 
immune response and are vital to protect the organism from the aggressive effector 
mechanisms of the immune system.  
 
FIGURE 1.1: APC:T cell interaction. The MHCII molecule on the APC presents the 
antigen to the T cell receptor (TCR). Together with the B7:CD28 binding, APCs can 
activate T cells and induce the clonal expansion of T cells (modified from Janeway et 
al., 2005). 
 
 Extracellular pathogens and proteins internalized by APCs are either recycled 
to the plasma membrane or transported to the lysosome for fragmentation and then 
presented via MHC class II (MHCII) to CD4+ T cells to induce an immune response 
(Janeway et al. 2005; Watts, 2004). Proteins are enclosed by endosomes, which 
become increasingly acidic as they progress from early to late endosome while 
travelling into the interior of the cell and eventually fuse with the lysosome. Proteases 
as well as glycosidases and lipases are present in endolysosomes and are activated 
by low pH yielding protein degradation into peptides. Cells can also generate an 
oxidative burst, including the production of nitric oxide (NO). NO and potentially other 
oxidants process the antigen to low molecular weight (MW) peptides. In order to 
APC 
TCR 
antigen 
MHCII 
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present the antigen to a CD4+ T cell, the peptide needs to be loaded onto the MHCII 
molecule (Smith et al., 1998; Jardetzky et al., 1990). On the contrary to MHCI, the 
MHCII molecule is only present on professional APCs. The MHCII molecule consists 
of a noncovalently bound complex of two transmembrane glycoprotein chains, the α 
and β chains. The MHCII molecule possesses - on the contrary to the MHCI molecule 
- open ends on the peptide-binding groove. An uncontrolled early binding is 
prevented by the invariant chain which fills and blocks the peptide binding groove of 
MHCII as well as targets it to an acidic endosomal compartment. The MHCII:invariant 
chain complex enters the acidic endosomal pathway where activated proteases 
cleave the invariant chain leaving a short fragment of it, called CLIP (class II-
associated invariant-chain peptide). Intracellular antigen loading of MHCII is 
dependent on HLA-DM, a MHCII-like molecule in humans (H-2M in mice), which is 
found predominantly in the MHCII compartment (MIIC) (Denzin and Cresswell, 1995). 
It first binds to the MHCII molecule, catalyzes the release of the CLIP fragment from 
the MHCII binding groove, stabilizes the MHCII molecule to prevent aggregation and 
aids in rapid and tight binding of peptides to the empty MHCII molecule. The 
MHCII:peptide complex is then transported from the lysosome to the cell surface and 
the peptide presented to CD4+ T cells (Abbas et al., 2000).  
 Upon recognition, the CD4+ T cells are specialized to activate other effector 
cells of the immune system, e.g. macrophages, which are activated to kill the 
intravesicular pathogens they harbour or B cells to secrete immunoglobulins against 
foreign molecules. The B-cell antigen receptors are a membrane-bound form of the 
antibodies, which will be released upon activation, plasma cell differentiation and 
proliferation of the B cell with a specific antigen. The MHCII:peptide complex must be 
stable at the cell surface. Otherwise, the pathogen in the infected cell could escape 
detection or be picked up by MHC molecules of an uninfected cell and be wrongfully 
destructed by cytotoxic T cells (Janeway et al., 2005).  
 T cells bear about 30,000 antigen-receptor molecules on their surface 
(Janeway et al., 2005). These receptors are termed T-cell receptor (TCR). The TCR 
receptor is a heterodimer and consists of two different polypeptide chains, the TCRα 
and the TCRβ, which are linked by a disulfide bond. The TCR on their cell surface 
recognizes processed and presented peptide antigens. These α:β heterodimers have 
a similar structure to the Fab fragment of an immunoglobulin molecule. They account 
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for antigen recognition by most T cells (Janeway et al., 2005). About 5 % of the T 
cells though possess a TCR consisting of γ and δ chains.  
 
 
1.4 DCs stimulate T cell activation  
The mature DCs interact with T cells by forming an immunological synapse made up 
of MHCII:peptide complexes on the DC and the TCR on the T cells. Other ligand 
interaction within the synapse are CD40 and CD40 ligand (CD40L), CD80 (B7.1) or 
CD86 (B7.2) and CD28, DC-SIGN and intercellular adhesion molecule 3 (ICAM-3), 
ICAM-1 or ICAM-2 to LFA-1, and LFA-3 to CD2, each on the DC and the T cell 
surface (Steinman, 2000). This specific interaction activates the T cell by intracellular 
signalling pathways, and induces their differentiation and proliferation. Naïve T cells 
transiently bind to APCs through low-affinity LFA-1:ICAM-1 interactions for screening 
the MHC molecules on the APC surface for the presence of specific peptide 
(Janeway et al., 2005). Once a naïve T cell recognizes its MHC:peptide ligand, 
signalling through the TCR induces a conformational change in LFA-1, which greatly 
increases its affinity for ICAM-1 and ICAM-2. The conformational change in LFA-1 
stabilizes the T cell:APC association and prolongs cell-cell contact which can persist 
for several days. During that time, the naïve T cell proliferates and its progeny, which 
also adhere to the APC, differentiate into armed effector T cells (Janeway et al., 
2005). By secreting specific cytokines, DCs can further direct T cell development 
towards either Th1 or a Th2 phenotype (de Jong et al., 2005). Interaction of immature 
or tolerogenic DCs with T cells can result in T cell deletion, anergy, or the generation 
of Treg cells (Roncarolo et al., 2001).  
 
 
1.5 Superantigens and T cell-independent antigens 
In contrast to conventional processed antigens, superantigens do not require 
internalization for their biological activity. Superantigens are for example, the toxic 
shock syndrome toxin-1 (TSST1) or staphylococcus aureus enterotoxins. 
Superantigens can bind to the α chain of MHCII on the APC surface and a specific β-
chain of the αβTCR on a CD4+ T cell. Immunoglobulins and TCR are highly variable 
molecules and possess a variable (V) region that binds to antigens. Bacterial 
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superantigen toxins hyperstimulate the immune system through the direct activation 
of APCs and T cells, which possess TCR-specific variable β-chain (Vβ) elements 
(Marrack and Kappler, 1990). Fragmentation of the superantigens, as in e.g. antigen 
processing, would only lead to loss of their biological activity. Their biological activity 
depends on binding as an intact protein to the outside surface of an MHC class II 
molecule which has already bound peptide (Janeway et al., 2005). 
 MHCII-mediated CD4+ T cell activation has been considered to be strictly 
limited to protein antigens (Watts and Powis, 1999). When presented to T cells by 
MHCII, peptide antigens generally elicit a T cell-dependent immune response typified 
by the production of Th1 or Th2 cytokines as well as immunoglobulin G (IgG) and the 
induction of immunologic memory.  
 In contrast, the immunologic response to polysaccharide antigens is 
considered T cell-independent and characterized by a primary humoral immune 
response of IgM production, rare IgG class switching, and no immunologic memory 
(Lesinski and Westerink, 2001; Abbas et al., 2000). Vaccine research with 
carbohydrate-protein conjugates has demonstrated that attachment of some 
polysaccharides or oligosaccharides to immunogenic carrier proteins like tetanus 
toxoid (TT) can generate an antigen capable of inducing significant IgG production 
(Kasper et al., 1996), T cell activation, and immune memory specifically directed 
toward the carbohydrate (Baker et al., 1999).  
 
 
1.6 Zwitterionic polysaccharides as T cell-dependent antigens 
Until recently, MHCII was only known to present protein peptides or superantigens. 
Indeed, most bacterial polysaccharides usually find their end station in lysosomes of 
antigen-presenting cells (APCs) without further processing or presenting on the APC 
surface to T cells (Watts, 2004). Thus, the discovery of the MHCII pathway also being 
responsible for carbohydrate antigen presentation and ultimately T cell recognition 
alters the fundamental model of MHCII-antigen binding. Recently, in vivo and in vitro 
studies showed that some polysaccharides of certain commensal bacteria are 
transported from lysosomes to the cell surface where they are presented by MHCII to 
activate CD4+ T cells in vitro and induce CD4+ T cell-dependent abscesses in vivo 
(Velez et al., 2009; Cobb and Kasper, 2008; Stephen et al., 2007; Cobb et al., 2004; 
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Kalka-Moll et al., 2002). The CD4+ T cell activation by bacterial polysaccharides has 
been shown to depend on retrograde transport via MHCII tubules of the bacterial 
polysaccharides. The functional role of HLA-DM helps the bacterial polysaccharide to 
compete with peptides for MHCII binding (Cobb and Kasper, 2008; Stephen et al., 
2007).                  
         Few naturally occurring polysaccharides such as PSA1 and PSA2, Sp1, and 
CP5 from the commensal bacteria Bacteroides fragilis, Streptococcus pneumoniae 
serotype 1 and Staphylococcus aureus, respectively, are characterized by opposite 
charge motifs on each repeating unit and are therefore called zwitterionic 
polysaccharides (ZPS) (Choi et al., 2002; Wang et al., 2000; Lindberg et al., 1980). 
This zwitterionic motif is critical for antigenic function of ZPSs. Removal of either a 
positive or negative group has been demonstrated to result in an immunologically 
inert carbohydrate unable to stimulate CD4+ T cells (Tzianabos et al., 1993).  
 
 
1.7 Peritonitis and abscess formation as a T cell-dependent immune response 
Secondary peritonitis, which is by far the most common form of peritonitis, results 
from loss of integrity in the gastrointestinal tract, leading to contamination of the 
peritoneal space by commensal intestinal bacteria (Farthmann and Schoffel, 1998). 
Intraperitoneal abscesses develop as a classic host response to bacterial infection 
that follows colonic leakage of commensal intestinal bacteria. It might serve to 
localize the pathogens within the peritoneal cavity. Intraperitoneal abscesses can be 
seen in patients with inflammatory bowel diseases (IBD) such as Crohn’s disease or 
ulcerus colitis. Despite improved diagnostic modalities, potent antibiotics, modern 
intensive care, and aggressive surgical treatment, up to one third of patients still die 
from generalized peritonitis (Marshall and Innes, 2003). The cornerstones of 
successful surgical treatment for generalized peritonitis are thorough peritoneal 
lavage, drainage of localised abscesses, repairing, which may require removal of the 
contaminating source, and effective drainage of the peritoneal cavity. However, even 
with optimal therapy including the administration of antibiotics, residual abscesses 
form in many patients, resulting in substantial morbidity and mortality (Nichols, 1985).  
 Abscess formation is known to be a CD4+ T cell-dependent immune response 
induced by ZPS (Tzianabos et al., 1993). The zwitterionic charge promotes CD4+ T 
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cell-dependent abscess induction in experimental murine and rat models (Tzianabos 
et al., 2000b). Chemical abrogation of the zwitterionic charge demonstrated that the 
zwitterionic nature of ZPS is critical to its ability to induce abscess formation. 
Elimination of the charged groups on each repeating unit does not induce CD4+ T 
cell-dependent immune responses in vitro and in vivo (Tzianabos et al., 1993). Vice 
versa, uncharged polysaccharides induce T cell-dependent immune responses after 
they are modified to possess a zwitterionic charge (Tzianabos et al., 2000a, 1994, 
and 1993). In this study, experiments are performed with the ZPS model antigen Sp1 
from Streptococcus pneumoniae serotype 1. 
 
 
1.8 Streptococcus pneumoniae  
S. pneumoniae is a spherical sometimes ovoid gram-positive bacterium, which is an 
oxidase- and catalase- negative, non-sporing, non-motile, alpha-hemolytic, and 
aerotolerant anaerobe diplococcus (Cowan and Steel, 1993). It is a significant human 
pathogen as it is a major cause of pneumoniae. Other infections caused by S. 
pneumoniae are meningitis, otitis media, bacteraemia, endocarditis but also brain 
abscesses as well as peritonitis. In humans, S. pneumoniae serotype 1 is 
predominantly detected in specimens from abscesses located in lungs, muscles and 
soft tissue (personal communication with R. R. Reinert, National Reference 
Laboratories for Pneumococci, Aachen). The capsule is the main virulence factor 
which permits also a discrimination of upto 91 different known serotypes till date. 
Sp1, the zwitterionic polysaccharide used in this study, is an integral part of the 
capsule of S. pneumoniae serotype 1.  
Two vaccines are available today which confer immunization to the capsular 
components of S. pneumoniae. One is called Pneumovax 23® which is a 23-valent 
pneumococcal-free vaccine composed of purified polysaccharides derived from the 
surface capsule of the bacterium (de Roux et al., 2008). These polysaccharide 
antigens generally elicit T cell-independent immune responses and are 
recommended for over 2 year-olds (Pebody et al., 2005). The other one is called 
Prevenar® and is a conjugate vaccine which is recommended for infants and toddlers 
upto 2 years of age. In this vaccine the capsular polysaccharide is conjugated with a 
protein to induce a T cell-dependent response against seven serotypes 
(Bernatoniene and Finn, 2005, Reinert, 2004). 
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1.9 ZPS and Sp1 structure 
Sp1 is a right handed helix with eight residues per turn and a pitch of 20 Å (Choi et 
al., 2002). Sp1 is a linear polymer of an average molecular size of 70 kDa 
corresponding to 130 trisaccharide repeating units. Each tri-saccharide unit  
possesses two negatively charged carboxyl groups and one positively charged amino 
group which identifies Sp1 as ZPS (Lindberg et al., 1980) (Fig. 1.2).  
 
  
 
 
 
 
 
 
FIGURE 1.2: Structure of Sp1. The molecular size of one Sp1 trisaccharide unit is 
537 Da. Each Sp1 repeating unit contains of one positively charged galactose (2-
acetamido-4-amino-2,4,6-trideoxygalactose-AAT) and two negatively charged 
galacturonic acids (GalA) and illustrate the zwitterionic nature of the polysaccharide 
(Choi et al., 2002; Stroop et al., 2002; Tzianabos et al., 1993). 
 
 
1.10 ZPS-mediated CD4+ T cell activation 
Sp1 is endocytosed, processed and loaded onto newly synthesized MHCII molecules 
by means of HLA-DM (Cobb et al., 2004). The MHCII:Sp1 complex is transported via 
tubuli in DCs from the lysosomal compartment to the cell surface where the Sp1 is 
presented to T cells to induce a CD4+ T cell-dependent immune response (Stephen 
et al., 2007) (Fig. 1.3).  
Direct T cell-interaction with the MHCII of APCs is essential for a ZPS-mediated 
CD4+ T cell proliferation (Kalka-Moll et al., 2002). The high density of charge on Sp1 
molecules facilitates electrostatic interactions between APCs and T cells (Choi et al., 
2002). ZPS promote CD4+ T cell proliferation via the first signal which is mediated by 
the MHCII molecule on the APC and initiated by the TCR and the CD3 molecule on 
the T cell. Essential is also the second signal that is provided by the co-stimulatory 
molecules B7.2 (CD86) and CD40 of the same activated APCs to CD28 and CD40L 
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of the same T cell (Stephen et al., 2005). ZPS requires these co-stimulatory 
molecules to promote intra-abdominal abscess formation through CD4+ T cell 
activation (Tzianabos et al. 2000b; Stephen et al., 2005). Abscess formation in 
response to ZPS failed in animals lacking αβCD4+ T cells (Chung et al., 2003). The 
CD40L interaction on T cells with the CD40 on APC is critical to elevate expression of 
co-stimulatory molecules and induces the expression of a variety of cytokines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.3: Model of Sp1 internalization, processing and presentation to CD4+ 
T cells. [1], [2] ZPS is internalized by DCs either by macropinocytosis or receptor-
mediated endocytosis. [3] ZPS-internalization induces an oxidative burst in the DC 
that is required for the processing of ZPS antigens to fragments. [4] The late 
endosome containing the ZPS fragments fuses with the MHCII- and DM-containing 
exocytic vesicle. [5] DC maturation is induced by for example LPS and leads to high 
protease and glycosidase activity in the MIIC. [6] DM catalyses the exchange of CLIP 
for the ZPS fragment antigen contained within the MIIC. [7] The MHCII:ZPS fragment 
complex is transported via tubuli from the endolysosomal compartment to the cell 
surface. [8] After the membrane fusion of the tubuli, the antigen is presented to the T 
cell where [9] then the DC/T cell engagment and T cell activation occur (Cobb et al., 
2004, Stephen et al., 2007, Cobb and Kasper, 2008). 
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1.11 Cytokines involved in T cell-dependent immune responses 
Cytokines gain increasing importance in CD4+ T cell-induced abscess formation. It 
has been suggested that cytokines may be responsible for triggering the migration of 
immune cells into the peritoneal cavity following contamination with B. fragilis (Gibson 
et al., 1996). Cytokines, such as tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-
6, IL-12, IL-15, and IL-18, are involved in T cell activation and proliferation 
(Banchereau et al., 2000). Gibson et al. (1998) demonstrated that ZPS PSA1 induces 
the production of TNF-α and IL-1α on peritoneal cells which act as significant 
immune mediators for abscess formation. If TNF-α is blocked, expression of the 
ICAM-1 is significantly reduced so that accumulation of polymorphonuclear 
leukocytes (PMNLs) within the abdominal cavity, the hallmark of peritoneal sepsis, is 
inhibited. Furthermore, PSA1 stimulates the secretion of chemokines, such as IL-8, 
from T cells (Tzianabos et al., 2002). In mice challenged with whole B. fragilis, CD4+ 
T cells mediate abscess formation by an IL-17-dependent mechanism (Chung et al. 
2003). Treatment of mice with an IL-17-neutralizing antibody significantly inhibited 
abscess formation. 
During sepsis and peritonitis, along with TNF and IL-1, IL-6 is also an important 
mediator of immunologic alterations in the host (Ertel et al., 1991; Shalaby et al., 
1989). High titres of IL-6 result from complex amplification mechanisms involving IL-1 
and TNF (Xu et al., 2007; Brouckaert et al., 1993). Evidence suggests that IL-6 is the 
most potent of the proinflammatory cytokines because it stimulates the expression of 
the broadest spectrum of acute phase proteins in inflammation and infection (Gomez 
et al, 2006; Helle et al., 1988). IL-6, a pleiotropic inflammatory cytokine, is produced 
by a variety of cells and acts on a wide range of tissues (Hirano, 1998). It stimulates 
the activation, survival, proliferation of CD4+ T cells and acts on T cells as an anti-
apoptotic factor (Takeda et al., 1998; Teague et al., 1997; Van Snick, 1990; Lotz, et 
al. 1988). IL-6 prevents apoptosis of normal and resting T cells in the absence of 
additional cytokines. IL-6 has also been identified as a migration factor for human 
primary T cells (Weissenbach et al., 2004). In vitro experiments showed chemotactic 
activity of IL-6 on peripheral blood lymphocytes, lymphokine-activated killer cells, 
CD4+ and CD8+ T lymphocytes (Cao et al., 1998; Delens et al., 1994; Bacon et al., 
1990). Additionally, IL-6 has been linked to T cell-dependent immune diseases and 
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autoimmune diseases such as the inflammatory bowel diseases, ulcerative colitis and 
Crohn’s disease (Mitsuyama et al., 2006; Van Kemseke et al., 2000). 
 
 
1.12 Toll-like receptor signalling and adapter molecules 
The innate immune system provides an immediate but non-specific defence against 
pathogens by recognizing specific pathogen-associated molecular patterns (PAMPs) 
(Kawai and Akira, 2007; Janeway, 1989). The innate immune system recognizes 
PAMPs by means of pattern-recognition receptors (PRR) (Sanjuan et al., 2009; Ishii 
et al., 2008). Such PRRs include the Toll-like receptors (TLR), homologues of the 
Drosophila Toll gene (Pasare and Medzhitov, 2004).  
 Until now, 13 murine TLRs and 10 human TLRs have been identified of which 
each recognizes several different PAMPs (Kumagai et al., 2008; Pasare and 
Medzhitov, 2004). TLRs that reside extracellularly on the cell membrane or 
phagosomes are e.g. TLR1/2 or 2/6, TLR4, TLR5 and TLR11, which recognize 
proteoglycans or lipopeptides of gram-positive bacteria, lipopolysaccharides (LPS) 
from gram-negative bacteria, flagellin and propellin, respectively. TLR3, TLR7/8 and 
TLR9 are expressed exclusively intracellularly in endosomes and recognize nucleic 
acids: dsRNA, ssRNA and ssDNA (containing CpG motifs), respectively (Kumagai et 
al., 2008; Uehara and Takada, 2007). An overview for the common TLRs and their 
ligands and adapter molecules are given in Fig. 1.4.   
All TLRs elicit conserved inflammatory pathways. The proximal events of TLR-
mediated intracellular signalling are initiated by Toll/interleukin-1 receptor (TIR)-
domain-dependent heterophilic interactions with TIR-domain-containing adapters. 
These cytoplasmic adapters, which regulate TLR-mediated signalling pathways by 
providing specificity for individual TLR downstream signalling cascades are myeloid 
differentiation primary response protein 88 (MyD88), TIR domain-containing adapter 
protein (TIRAP)/Mal, TIR domain-containing adapter inducing IFNβ (Trif) and Trif-
related adapter molecule (TRAM) (Takeda and Akira, 2005; Akira and Takeda, 2004; 
Martin and Wesche, 2002). TLR signalling can occur either in a MyD88-dependent 
(TLR1, 2, 4, 5, 6, 7, 8, 9, 11) or in a MyD88-independent (TLR3, 4) manner. TLR4 
can activate NF-κB via the MyD88-dependent pathway as well as the TRIF-
dependent (MyD88-independent) signalling pathway. TLR2 and TLR4 recruit TIRAP 
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and MyD88 for the MyD88-dependent pathway and TLR4 recruits TRAM and Trif in 
the MyD88-independent pathway.  
The triggering of TLRs (e.g. TLR4) on DCs leads to the induction of co-
stimulatory signals (e.g. MHCII, CD80 and CD86) and to the production of cytokines 
(e.g. IL-6) that orchestrate T cell recruitment, activation, differentiation and survival 
and are essential for the induction of adaptive immune responses (Ulevitch and 
Tobias, 1995; Yamamoto et al., 2002; Pasare and Medzhitov, 2003, Kubo et al., 
2004; Liang et al., 2004; Yang et al., 2004). 
 
 
 
FIGURE 1.4: Toll-like receptors. Extracellularly located TLRs are TLR1/2 or 
TLR2/6, TLR4, TLR5, and TLR11 and recognize lipopeptides, LPS, flagellin and 
propellin, respectively. Intracellularly located TLRs are TLR3, TLR7/8 and TLR9 and 
recognize dsRNA, ssRNA and CpG DNA, respectively. All TLRs, except TLR3 
mediate MyD88-dependent signalling (modified from Kawai and Akira, 2006). 
 
 
1.13 NF-κB activation and translocation 
Upon TLR stimulation with ligands, MyD88 death domain interacts with the death 
domain of IL-1 receptor-associated kinase (IRAK) (Kawai and Akira, 2007). IRAK is 
phosphorylated and associates with TNF receptor-associated factor 6 (TRAF-6), 
which activates transforming growth factor-β (TGFβ)-activated proteinkinase 1 
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(TAK1) in an ubiquitin-dependent manner (Chen, 2005). TLR-signalling leads mainly 
to the activation of the transcription factor “nuclear factor of ‘kappa-light-chain-gene-
enhancer’ of activated B-cells” (NF-κB) which induces specific gene transcription 
(Kawai and Akira, 2006, Moynagh, 2005).  
 The NF-κB family comprises out of five members: RelA (p65), RelB, c-Rel, 
p105 (NF-κB; a precursor of p50) and p100 (NF-κB2; a precursor of p52) (Karin and 
Greten, 2005). NF-κB proteins form homo- or hetero-dimers. Under non-stimulated 
conditions, NF-κB is inactive in the cytoplasm and bound to family members of 
inhibitory proteins known as IκB proteins (Kawai and Akira, 2007). The IκB kinase 
(IKK) complex consists of IKKα and IKKβ protein kinases and a regulatory molecule, 
IKKγ/Nemo. TAK1 activates the IKK complex that leads to NF-κB activation (Fig. 1.4). 
Upon stimulation with various TLR ligands, IKK complex phosphorylate e.g. IκB-α, at 
serine residues. Phosphorylated IκB-α is then degraded via the proteosomal 
pathway, releasing the NF-κB dimers as for e.g. p65 to translocate from the 
cytoplasm to the cell nucleus (Kawai and Akira, 2006). A TRAF-6-mediated activation 
of NF-κB is required for the transcription of inflammatory cytokines (Fig. 1.5). 
 Though many TLR ligands have been identified so far, which contain 
carbohydrate moieties such as LPS, so far the noncarbohydrate portion of the 
molecules seemed critical for TLR ligation and activation (Alexander and Rietschel, 
2001). Only recently, pure carbohydrates have been suggested as potential TLR 
ligands and to activate TLR signalling. Polysaccharides from cell culture of 
Acanthopanax senticosus in particular leads to APC activation via TLR (Han et al., 
2003). More interestingly, the B. fragilis ZPS PSA1 has been demonstrated to 
stimulate APCs through a TLR2-dependent mechanism. TLR2 was revealed to be 
the receptor for PSA to activate NF-κB and hence lead to co-stimulatory molecule 
expression as well as cytokine production (Wang et al., 2006). This study 
investigates further TLRs for ZPS-mediated immune responses.  
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FIGURE 1.5: NF-κB activation and translocation. TLR4 activates the MyD88-
dependent or the Trif-dependent pathway. In the Myd88-dependent pathway, TRAF-
6 activates TAK1, which then activates the IKK complexes or the mitogen-activated 
protein (MAP) kinases. IKK complex leads to ubiquitination and phosphorylation of 
IκB-α,  which releases NF-κB subunits, e. g. p65 to translocate to the nucleus. MAP 
kinases activate first JNK, p38 and ERK to then activate AP-1. In the Trif-dependent 
pathway, TLR4 recruits TRAM, which interacts with TBK1 which together with IKKi 
mediates phosphorylation of IRF3. Activation of IRF3, NF-κB and AP-1 is required for 
induction of type I IFN, particularly IFNβ. TLR3, which resides in endosomal vesicles, 
utilizes Trif but not MyD88, TIRAP or TRAM for its signaling (modified from Kawai 
and Akira, 2006). 
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1.14 Aim of the present study 
Microbial glycobiology is still a vast field of many unanswered questions, especially 
when it comes to ZPS which have the potential to induce CD4+ T cell-dependent 
immune responses in vitro. ZPS are also capable of inducing abscess formation in 
vivo in a CD4+ T cell-dependent manner (Stephen et al., 2007; Cobb et al., 2004; 
Kalka-Moll et al., 2002; Tzianabos et al., 1993).  
 To date, very little is known about the role of IL-6 in Sp1-mediated abscess 
formation in vivo and CD4+ T cell responses in vitro. The purpose of this study is to 
shed light on the IL-6 secretion following Sp1 challenge and its involvement in 
abscess formation. Professional APCs will be tested for their ability to internalize Sp1 
and to secrete IL-6 upon Sp1 uptake. The effect of IL-6 on Sp1-induced T cell 
migration and T cell apoptosis will be explored. Further, Sp1 will be tested as a TLR 
ligand to activate NF-κB and IL-6 expression.  
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Consumables 
 
Item Company, Place                         g                       
15 mL polypropylene test tubes, Cellstar Greiner Bio-One, Frickenhausen 
50 mL polypropylene test tubes, Cellstar Greiner Bio-One, Frickenhausen 
Cannula (sterile) 
 26 G Terumo Neolus, Belgium 
 20 G, 27 G BD Microlance3, Spain 
Cell strainer (sterile), 40 µm, 70 µm, 100 µm BD Falcon, Heidelberg 
Cell scraper (25 cm) Sarstedt, Nümbrecht 
Combitips plus Eppendorf, Hamburg 
Cover slips (glass) ∅12 mm, ∅ 18 mm Menzel, Braunschweig 
Cover glasses for Haemocytometer Superior Marienfeld Laboratory  
   Glassware, Lauda-Königshofen 
Cryo vials (sterile) 1.8 mL, Cellstar Greiner Bio-one, Frickenhausen 
Eppendorf tubes, 0.5 –2.0 mL Sarstedt, Nümbrecht 
FACS tubes BD Falcon, Heidelberg 
Filters (sterile), 0.45 µm, 0.22 µm Nunc, Langenselbold 
Lab-Tek Slide Culture Chambers Nunc, Langenselbold 
Lab-Tek®II Chamber #1.5 German Coverglass 
System Nunc, Langenselbold 
MatTek Poly-D-lysine-pre-coated 1.5 coverslips MatTek, USA 
 glass bottom plates  
Microscope slides Engelbrecht, Edermünde 
Microtitre plates, 96 wells, non-sterile Nunc, Langenselbold 
Neubauer chamber/Haemocytometer Brand, Wertheim  
Parafilm M Brand, Wertheim 
Pasteur pipette (230 mm) Volac, Wertheim 
Petri Dish, 90 mm  Nunc, Langenselbold 
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Consumable Company, Place                          j  
Plastic cuvettes Sarstedt, Nümbrecht 
Transfer pipettes (sterile) Sarstedt, Nümbrecht 
 5 mL, 10 mL, 25 mL, and 50 mL  Sarstedt, Nümbrecht 
Sealing tape Dynex, Frankfurt 
Syringes (sterile), 1 mL, 5 mL, 10 mL BD Falcon, Heidelberg 
Syringes, Micro-fine (sterile), 1 mL, 29 G, U-100 BD Falcon, Heidelberg 
Steriflip, 0.2 µm pore size Millipore, Schwalbach 
Tissue culture plates 
 6 wells, 12 wells, 24 wells, 96 wells Nunc, Langenselbold 
Tissue culture dishes Nunc, Langenselbold 
Tissue culture flasks Nunc, Denmark 
 
 
2.1.2 Instruments 
 
Item  Company, Place                          j  
Autoclave Fritz Gössner GmbH, Hamburg 
Blotting chamber Criterion, Electroporation unit Biorad, Munich 
Centrifuge  
 Multifuge 3 S-R  Heraeus, Hanau 
 Multifuge 4KR Heraeus, Hanau 
 Biofuge fresco, Table top Heraeus Instruments, Hanau  
Centrifuge-rotors, max. 4600 rpm Heraeus, Hanau 
Conductivity measurement device, Cond 340i WTW, Weilheim 
Electrophoresis power supply, PowerPac-300 Biorad, Munich 
Fluorescent Activated Cell Sorter  
 (FACS System) Calibur BD, Heidelberg 
Fast Protein Liquid Chromatography ÄKTA(FPLC) Amersham Biosciences, Munich 
Fraction collector, Frac-950 Amersham Biosciences, Munich 
Freezer (-20°C) Liebherr Premium Liebherr, Ochsenhausen 
Freezer (-80°C), Hera Freeze, Kendro Heraeus, Hanau 
Fridge Liebherr, Ochsenhausen  
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Instrument Company, Place                          j  
Gel-documentation unit, Gel Doc 1000 Biorad, Munich 
Ice machine Ziegra, Isernhagen 
Incubators 
 CO2 incubators, Thermo Scientific Forma Thermo, Langenselbold 
 Incubator with shaker, Innova 4200 New Brunswick Scientific, USA 
IR lamp, Clatronic LGA, Nürnberg 
Laminar flow, LaminAir Holten, Thermo Scientific Thermo, Langenselbold 
Liquid nitrogen tank, Arpege 170 AirLiquide, Langenfeld 
Lyophiliser, Lyovac GR2 SRK Systemtechnik, Riedstadt 
Magnetic stirrer, IKA, Combimag, RCH Janke & Kunkel AG, Staufen 
Magnet for cell isolation  
 MidiMacs MiltenyiBiotec, Bergisch-Gladbach 
 EasySep StemCell, Cologne 
Microscope 
 Light microscope (cell count), Axiovert-25 Zeiss, Cologne 
 Fluorescent microscope Olympus AH2 & IX81 Olympus, Hamburg 
 Confocal laser scanning microscope FV1000 Olympus, Hamburg 
Micropipette 
 0.2 - 2 µL, 2 - 20 µL, 20 - 200 µL, 100 - 1000 µL Thermo LabSystems 
Multipipette plus Eppendorf, Hamburg 
NANOpure Diamond Reinstwassersysteme Werner, Barnstedt 
NMR DRX500 Bruker Biospin, Switzerland 
Orbital Shaker, MR3000 Heidolph, Schwabach 
pH-meter 766 Calimatic Knick, Zweibrücken 
Pipette boy, Accujet Brand, Wertheim 
Refractive Index (RI) Detector Varian 356LC Varian, Darmstadt 
Rotator, Heidolph Reax-2 Heidolph, Schwabach  
Scales, Sartorius Laboratories Sartorius, Heidelberg 
Special accuracy weighing machine, Genius Sartorius, Heidelberg 
Spectral photometer, Genesys 20 Thermo, Langenselbold 
Stirred Ultrafiltration Cell (Amicon) Millipore, Schwalbach 
Thermo mixer comfort, heating block Eppendorf, Hamburg 
Vacuum pump, Model RV3 Edwards, Kruetzwertheim 
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Instrument Company, Place                          j  
Vortex, Genie 2 Scientific Industries, USA 
Water bath, GFL 1086 GFL, Burgwedel 
 
 
2.1.3 Buffers, media and solutions 
 
All buffers and solutions were prepared or diluted with either Nanopure water, sterile 
aqua ad iniectibilia or PBS. 
 
Item  Company, Place                         d 
Aqua ad iniectabilia Delta Select, Pfullingen 
Phophate buffered saline-Dulbecco (PBS) Biochrom AG, Berlin 
VLE (very low endotoxin)-RPMI 1640 Medium Biochrom AG, Berlin  
 
 
2.1.4 Chemicals and reagents 
 
Item  Company, Place                         d 
Complete protease inhibitor cocktail tablet Roche, Switzerland 
DTT(1,4 Dithio-DL-threitol) Fluka, Sigma, Steinheim 
EDTA(Ethylenediaminetetraacetic acid) Sigma, Steinheim 
EGTA  
(Ethyleneglycol bis (2-aminoethyl) tetraacetic acid  Roth, Karlsruhe 
Formaldehyde Roth, Karlsruhe 
Glycerol  Merck, Darmstadt 
Hepes  Gibco, Karlsruhe 
MgCl2  Sigma, Steinheim 
NaCl  Roth, Karlsruhe 
NaF Merck, Darmstadt 
NaVo3 Roche, Switzerland 
Nonidet P40 Fluka, Steinheim 
PMSF (Phenylmethylsulfonyl fluoride) Roche, Mannheim 
Tween®20 (Polyoxyethylenesorbitanmonolaurate) Sigma, Steinhein 
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2.1.5 Purification of Streptococcus pneumoniae type 1 capsular polysaccharide (Sp1) 
 
Item  Company, Place / Composition  
Software:   
 BCA assay Revelation Version 4.06 
 FPLC UNICORNTM 3.2 
2 M NaOH  
2 M Acetic acid 
Phenol (90%) Fluka, Steinheim 
H2SO4 (96%) Merck, Darmstadt 
10,000 Da MW cut-off membrane (Amicon) Millipore, USA 
BCA test kit Pierce, Rockfort, USA 
BCA plate reader, MRX Tc Revelation Dynex Technologies, Berlin 
Blood agar plate, Heipha Dr. Müller GmbH Heipha, Eppelheim 
Chromic sulphuric acid Riedel-de-Haen, Seelze 
D2O (Heavy H2O for NMR) Deutero GmbH, Kastellaun  
Dialysis buffer, pH 7.3: 0.05 M PBS with 0.05% NaN3  
LAL test Charles River, Charlston, USA 
Lyophilisate of S. pneumoniae serotype 1,  
 capsular polysaccharide  ATCC®, Mansas, USA 
Nitrogen flask Linde, Vulkan, Pullach 
Sodium azide (NaN3) (0.05%) Fluka, Steinheim 
Sephacryl® S-400 Pharmacia Biotech, Goettingen 
Ultrafiltration cell Amicon 
 
 
2.1.6 Labelling and modification of Sp1 
 
Item  Company, Place                         d  
Acetic anhydride Sigma-Aldrich, Steinheim 
Alexa Fluor® 488-Hydrazide Molecular Probes, Leipzig 
Alexa Fluor® 594-Hydrazide Molecular Probes, Liepzig 
Ethylene glycol Sigma, Steinheim 
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Item  Company, Place                         d  
PD10 column (desalting) GE Healthcare, Munich 
0.1 M sodium acetate buffer (pH 5.5)  
Sodium bicarbonate (NaHCO3) Biochrom AG, Berlin 
Sodium-m-periodate Sigma, Steinheim 
Sodium phosphate buffer (0.1 M, pH 7.0) 
 
 
2.1.7 Animals and abscess induction 
 
Item  Company, Place                         d 
Anti-mIL-6 purified rat monoclonal IgG1 (MP520F3) R&D Systems, Wiesbaden  
Ketavet®, API: Ketaminhydrochloride Pfizer, Berlin 
Rompun, 2%, API: Xylazinhydrochloride Bayer, Leverkusen 
SCCA (Sterile caecal content adjuvant)  caecal contents of C57BL/6 mice 
Mice: 
C57BL/6 wildtype mouse Charles River, France 
IL-6-deficient mouse Bluethmann, Switzerland 
TLR2-deficient mouse Kirschning, Munich 
TLR4-deficient mouse Kirschning, Munich 
MyD88-deficient mouse MPI, Freiburg 
 
 
2.1.8 Intracellular cytokine staining, flow cytometry and fluorescence microscopy 
 
Item  Company, Place / Composition  
Software:  
 FACS CELLQuest™Pro, BD 
 Fluorescence and light microscopy CellP Soft Imaging System 
 Confocal microscopy FluoView1000, FV10  
Binding buffer (Apoptosis assay) 0.1 M Hepes/NaOH (pH 7.4) 
   1.4 M NaCl 
   25 mM CaCl  
Cytofix/CytopermTM (ICS) BD Biosciences, Heidelberg 
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Item  Company, Place / Composition  
FACS buffer PBS with 10% FBS 
 
FACS fix (to fix cells, if delay in FACS analysis): PBS 
   1% FBS 
   2.5% Formaldehyde 
FACSRinse, FACSFlow, FACSClean BD Biosciences, Belgium 
Perm/WashTM Buffer (ICS) BD Biosciences, Heidelberg 
Staining Buffer (ICS) PBS (100 mL) 
   1% FBS (1 mL) 
   0.09% Sodium Azide (NaN3) 
Sodium hypochlorite solution Roth, Karlsruhe 
Starvation buffer (Apoptosis assay) RPMI-1640 supplemented with  
   0.1% FBS 
Apoptosis Detection Kit  BD Pharmingen, Heidelberg 
 Propidium iodide  
 Annexin V FITC conjugated   
Antibodies: 
CD4-APC anti-mouse (clone: RM4-5) BD Pharmingen, Heidelberg 
CD8-APC anti-mouse (clone: 53-6.7) BD Pharmingen, Heidelberg 
CD11b-PE anti-mouse (clone: M1/70) BD Pharmingen, Heidelberg 
CD11b-FITC anti-mouse (clone: M1/70) BD Pharmingen, Heidelberg 
CD11c-PE anti-mouse (clone: HL3) BD Pharmingen, Heidelberg 
CD11c-FITC anti-mouse (clone: HL3)  BD Pharmingen, Heidelberg 
CD16/CD32 Fc block anti-mouse (clone: 2.4G2) BD Pharmingen, Heidelberg 
CD45R/B220 PerCP anti-mouse (clone: RA3-6B2) BD Pharmingen, Heidelberg 
IgG1α anti-rat (clone: G28-5) BD Pharmingen, Heidelberg 
IL-6 FITC anti-mouse (clone: MP520F3) R&D, Wiesbaden-Nordenstadt 
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2.1.9 Immunohistochemistry 
 
Item  Company, Place / Composition 
Avidin Biotin Blocking Kit Vector Laboratories, Eching 
Cryostat CM3050S Leica Microsystems, Wetzlar 
DAB substrate Vector Laboratorie, Eching 
Fast red Dako, Hamburg 
Glass cuvettes Glassware, Wertheim 
Isopentane (2-Methylbutane) Roth, Karlsruhe 
Peroxidase blocking 0.3% H2O2 in Methanol 
Phosphatase  Dako, Hamburg 
Antibodies : 
IL-6, rat anti-mouse (clone : MP5-20F3) Biosource, Hamburg 
F4/80, rat anti-mouse (clone: A3-1) Serotec, Duesseldorf 
CD11c, hamster anti-mouse (clone: HL3) BD Pharmingen, Heidelberg 
Goat anti-hamster IgG:Biotin Serotec, Duesseldorf 
 
 
2.1.10 Cell culture and cell counting 
 
Item  Company, Place                         d 
2-Mercaptoethanol, 50 mM Gibco, UK 
CD11c (N418) micro beads, mouse MiltenyiBiotec, Bergisch-Gladbach 
DMSO Sigma, Steinheim 
Easy Sep, Mouse biotin selection kit Stem Cell, Cologne 
Erythrocyte lysis  NaCl (0.2%, 1.6%) 
Fetal Bovine Serum (FBS) LPS-free Gibco, Karlsruhe 
 Heat inactivated before use, 30 min at 56°C 
Heparin (5000 U)  dilute 1:1000 in PBS  
Hepes, 1 M Gibco, Karlsruhe 
Histopaque-1083 Sigma-Aldrich, Steinheim 
L-Glutamine, 200 mM (Low Endotoxin, LE) Biochrom AG, Berlin 
LPS, Escherichia coli 026:B6 Sigma, Steinheim 
Penicillin/Streptomycin (10,000 U) Biochrom AG, Berlin 
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Item  Company, Place                         d 
Sodium Pyruvate, 100 mM Gibco, Karlsruhe 
Trypan blue Sigma, Steinheim 
Antibodies: 
CD4 anti-mouse APC (clone: RM4-5) BD Pharmingen, Heidelberg 
CD8 anti-mouse APC (clone: 53-6.7) BD Pharmingen, Heidelberg 
CD34 biotin eBioscience, Cologne 
Cells: 
Bone marrow-derived dendritic cells 
Bone marrow-derived macrophages 
Lavage cells 
Splenocytes 
CD4+ T cells 
Peritoneal macrophages 
 
 
2.1.11 ELISA and nuclear extraction 
 
Item  Company, Place / Composition  
Software:   
Flow Cytomix Pro 1.0 Software BMSFFS/1.0 Bender MedSystems, Vienna 
ELISA: 
 mIL-6 ELISA Diaclone, Cologne 
 Multiplex Bead Assay Bender MedSystems, Vienna 
 Trans AM NFκB p65 Activation Assay ELISA Active Motif, Rixensart 
ELISA plate reader, Dyna Tech MR5000 Heidolph GPM, Tangstedt 
Methanol (CH3OH) J. T. Baker, Netherlands 
Modified Sp1 N-acetylated purified Sp1  
Nuclear extraction buffers 
 Buffer A: 10 mM Hepes pH 7.9 
   10 mM KCl 
   0.1 mM EDTA 
   0.1mM EGTA 
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 Item  Company, Place / Composition  
     add fresh: 
  1 mM DTT   
  1 mM PMSF  
 Buffer C: 20 mM Hepes pH 7.9 
 0.4 M NaCl 
 1 mM EDTA 
   1 mM EGTA 
    add fresh: 
   1 mM DTT  
TLR ligands: 
Flagellin (TLR5 ligand) Invivogen, France 
Gardiquimod (TLR7 ligand)  Invivogen, France  
LPS, Ultrapure E. coli 0111:B4 (TLR4 ligand) Invivogen, France 
ODN (TLR9 ligand) Invivogen, France 
Pam3CSK4 (TLR2 ligand) Invivogen, France 
Poly I:C (TLR3 ligand)  Invivogen, France 
 
 
2.1.12 Migration Assay 
 
Item  Company, Place / Composition  
Software: Wallac 1420 Manager 
BSA (Albumin Bovine Fraction) Serva, Heidelberg  
Buffer PBS with 0.1% BSA 
Calcein AM (0.5 mg/mL DMSO) Invitrogen, Spain 
CD4+ T cell Isolation kit, mouse MiltenyiBiotec, Bergisch-Gladbach 
Chemotaxis Plates (5 µm) Neuro Probe, USA 
Cotton swabs (Q-Tips) 
MACS Buffer: PBS pH7.2 
   0.5% BSA  
   2 mM EDTA 
MACS Multistand MiltenyiBiotec, Bergisch-Gladbach 
MACS Separation Columns MiltenyiBiotec, Bergisch-Gladbach 
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Item  Company, Place / Composition  
rmIL-6 cytokine R&D Systems, Wiesbaden  
SLC (Secondary Lymphoid Chemokine) Peprotech, Hamburg 
Wallac Victor2TM 1420 MultiLabel Counter Wallac, Finland 
 
 
2.1.13 Genotyping 
 
Item  Company, Place / Composition  
Software: Biorad Quantity one-4.4.4 Basic  
50 X TAE buffer pH 8.5 242 g Tris-Base (C4H11NO3) 
   57 mL Acetic Acid 
   37 g Na2EDTA x2H2O (TitriplexIII) 
Agarose UltraPureTM Invitrogen, Spain   
GeneRulerTM 100bp DNA Ladder  Fermentas, St. Leon-Rot 
DNeasy Blood & Tissue kit Qiagen, Hilden 
Ethidium bromide Roth, Karlsruhe 
Gel chamber Biorad, Munich 
Geldoc2000 Biorad, Munich 
IllustraTM PuReTaqTM Ready-To-GoTM PCR beads GE Healthcare, Munich 
PCR Thermocycler T3 & Tgradient Biometra, Goettingen 
Power Pac3000 Power Supply Biorad, Munich 
Primers  Sigma Genosys 
 
TABLE 2.1: IL-6 primer used for genotyping. 
___________________________________________________________________ 
Primer                  Sequence  Expected product size 
IL-6c-pr1 5’TTCCATCCAGTTGCCTTCTTGG3’  
IL-6c-pr2 5’TTCTCATTTCCACGATTTCCCAG3’   1314 bp (IL-6-/-), 174 bp (WT) 
IL-6-neo 5’CCGGAGAACCTGCGTGCAATCC3’  380 bp (IL-6-/-) 
___________________________________________________________________ 
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2.1.14 Surface expression and T cell proliferation 
 
Item  Company, Place / Composition  
γ-Radiator, Biobeam 8000/2000 Gamma-Service Medical GmbH 
Antibodies: 
Anti-CD14 
Anti-TLR2 
Anti-TLR4 
Anti-rat IgG FITC (2nd antibody) Sigma, Steinheim 
CD80  BD Pharmingen, Heidelberg 
CD86 BD Pharmingen, Heidelberg 
HLA-DR BD Pharmingen, Heidelberg 
Mouse IgG1 (clone: P3) eBioscience, Cologne 
Rat IgG2a (clone: R35-95) BD Pharmingen, Heidelberg 
TLR2 anti-mouse, purified (clone: T2.5) ebioscience, Cologne 
TLR4 anti-mouse, purified (clone: MTS510) BD Pharmingen, Heidelberg  
 
 
2.1.15 Western blot and whole cell extraction 
 
Item  Company, Place / Composition  
ECL Plus Western blotting detection reagents   
 Detection Reagent 1 and 2 Amersham Biosciences, UK 
 Hyperfilm Amersham Biosciences, UK 
Film Developer Curix60 Agfa, Cologne 
Fixer and Developer solutions Agfa, Cologne 
Immobilon-pSQ Transfer Membrane (0.2 µm) Millipore, USA 
Loading dye 5 mL Tris (pH 6.8) 
   10 mL Glycerol 
   20 mL SDS (10%) 
0.1 g Bromophenol blue 
LPS Salmonella abortus equi (ATCC 9842) Sigma, Steinheim 
Prestained protein marker Cell Signal, Frankfurt  
Semi-dry transfer cell  Biorad, Munich 
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Item  Company, Place / Composition  
SDS PAGE: 
 10% Resolving gel 30% acrylamide mix (26.6 mL) 
  1.5 M Tris pH 8.8 (20 mL) 
  10% SDS (0.8 µL) 
  10% APS (0.8 µL) 
  TEMED (0.032 µL) 
  Water (31.8 mL) 
 5% Stacking gel 30% acrylamide mix (5.1 mL) 
  1 M Tris pH 6.8 (3.675 mL) 
  10% SDS (0.3 µL) 
  10% APS (0.3 µL) 
  TEMED (0.03 µL) 
  Water (20.4 mL) 
Buffers: 
Antibody and blocking buffer 5% Milk powder 
  in 1 x TBS-0.01% Tween 20 
 
RIPA buffer 1 M Hepes (20 mM final conc.)
  5 M NaCl (350 mM final conc.) 
  Glycerol (20% final)  
  1 M MgCl2 (1 mM)  
  500 mM EDTA (0.5 mM)  
  0.1 M EGTA (0.1 mM)  
  Upto 50 mL with water 
    add fresh: 
  NaVo3  
  NaF  
  NP-40  
  Protein inhibitor 
 
Transfer buffer 5 x Tris/Glycin (1 L)  
  Methanol (1L) 
  10% SDS (5 mL) 
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Item  Company, Place / Composition  
  Water upto 5 L 
 
10 x SDS buffer Glycine (288 g) 
  Tris base (60 g) 
  SDS (20 g) 
  Water upto 2 L 
Wash buffer 1 x PBS with 0.1% Tween 20 
1° Antibodies: (diluted in antibody buffer) 
Phospho-IκBα (mouse mAb) (1:1000) Cell Signal, Frankfurt 
Total-IκBα (C-21, Rabbit) (1:400) Santa Cruz, Heidelberg 
α-Tubulin (mouse) (1:4000) Sigma, Steinheim 
2° Antibodies: (diluted in antibody buffer) 
Sheep-anti-mouse IgG, HRP linked (1:3000) GE Healthcare, Munich 
Donkey-anti-rabbit IgG, HRP linked (1:3000) GE Healthcare, Munich 
Sheep-anti-mouse IgG, HRP linked (1:3000) GE Healthcare, Munich 
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2.2 Methods 
 
2.2.1 Purification of Streptococcus pneumoniae type 1 capsular polysaccharide 
 
All instruments and devices used in the antigen purification process were 
deproteinated by treatment with sulphuric and chromic acid. The material was 
depyrogenated by heat inactivation for 4 h at 240°C or by treatment with 2 M NaOH. 
Heat-sensitive material such as plastic tubings of the FPLC and the ultrafiltration 
stirred cell (Amicon) were cleansed with 2 M NaOH-solution and pyrogen free water 
and subsequently sterilized in 4% formaldehyde. Buffer and solutions were sterile 
filtered through 0.22 µm-filter units.  
   Pneumococcal polysaccharide powder which contains the purified capsular 
components of S. pneumoniae type 1 is an intermediate product in the production of 
the 23-valent polysaccharide-vaccine against pneumococci from Merck & Co. 
(Whitehouse Station, New Jersey USA) and is marketed by the ATCC. The aim of the 
purification was to obtain the zwitterionic polysaccharide Sp1 from the whole capsular 
polysaccharide complex of S. pneumoniae obtained from ATCC and free it from C-
substance, proteins and nucleic acid.  
 
2.2.1.1 Base treatment to separate the C-substance 
Base treatment with 2 M NaOH cleaved the phospho-diester bonds of the C-
substance so that the low molecular weight fragments of the C-substance can be 
separated from Sp1 by the subsequent gel filtration chromatography. S. pneumoniae 
capsule lyophilisate (200 mg) was dissolved in 2 M NaOH (10 mg/mL) under 
vortexing, aliquoted into 2 mL Eppendorf tubes and incubated at 80°C for 1 h. 
Aliquots were then pooled and neutralized (pH 7) with 2 M acetic acid. The solution 
was ultrafiltrated in Amicon® stirrer cells fitted with a 10,000 Da cut-off membrane. 
The units were kept at 4°C and under 1.5 bar nitrogen pressure. Molecules larger 
than 10,000 to 30,000 Da were retained while smaller molecules were removed. By 
ultrafiltration, the solution was concentrated to a smaller volume. Simultaneously the 
ultrafiltration aided the filtrate to reach the same conductivity as the 0.05 M PBS-
NaN3 buffer, which was also used for equilibrating the FPLC. The concentrated 
supernatant was collected and filtered through a 0.22 µm sterile filter prior to loading 
onto the FPLC. 
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2.2.1.2 Gel filtration chromatography to separate Sp1 from C-substance and other 
contaminants 
Gel filtration chromatography was performed using Sephacryl S-400 high resolution 
columns. Sephacryl High Resolution is a composite medium prepared by covalently 
cross-linking ally dextran with N, N’-methylene bisacrylamide to form a hydrophilic 
matrix of high mechanical strength and broader fractionation range. The principle of 
gel filtration chromatography is that smaller molecules such as the C-substance will 
be retained longer in the matrix of the chromatography column as they require longer 
to diffuse in and out of the interspaces. Larger molecules such as Sp1 with an 
average size of 70 kDa, however, pass faster through the gel bed. Molecules can 
thereby be separated according to the molecular weight and size. 
   The S-400 HR column was connected to the semi automated ÄKTA FPLC 
system run by the UNICORNTM software. Sterility of the system was tested by 
incubating the run-through buffer on blood agar plates. Conductivity and refraction 
index were recorded throughout the run by the RI detector to detect polysaccharide 
contents in the solution. The polysaccharide solution with a volume of 50 mL was 
loaded and eluted with 500 mL buffer at a flow rate of 1.5 mL/min and collected in 4 
mL fractions.  
 
 
2.2.2 Analysis of purified Sp1 
 
2.2.2.1 Phenol/sulphuric acid assay for determination of carbohydrate content 
Fractions were additionally analysed for polysaccharide content by the phenol-
sulphuric acid method. Reaction of phenol and sulphuric acid with polysaccharide 
yield a yellow-brownish colour development. For this test, 200 µL of polysaccharide 
sample were mixed with 500 µL sulphuric acid and 5 µL phenol and swayed after 10 
min to check for a colour development. Positive control was sucrose and water was 
used a negative control. Fractions showing yellow-brownish colour development and 
were detected positive by the RI measurements were pooled together. The 
polysaccharide solution was dialysed and concentrated against water by Amicon® 
stirrer cells until the conductivity was equal to that of water (around 1 µSiemens). 
Carbohydrate-containing fractions were filtered through 0.22 µM sterile-flipped, 
lyophilized, and stored at 1 mg/mL (in PBS). Samples were checked for the presence 
of protein, LPS and Sp1.  
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2.2.2.2 Bicinchoninic acid test for determination of protein contamination 
The principle of the bicinchoninic acid (BCA) test is that peptide bonds in proteins 
reduce Cu2+ from the cupric sulphate to Cu1+ whereby colour change reactions from 
green to purple are proportionally stronger to increasing protein concentrations (Levin 
and Brauer, 1951). BSA was used as a positive and water as a negative control. BSA 
was prepared as a 1:2 dilution series from a fresh 2 mg BSA/mL stock solution for 
standardization and quantification of protein measurements. The assay was 
performed according to the manufacturer’s instructions. 
 
2.2.2.3 Limulus amoebocyte lysate test for determination of endotoxin contamination 
The Limulus amoebocyte lysate (LAL) is a sensitive method to measure endotoxin. It 
is based on the principle that endotoxin produces gelation in LAL that is readily 
recognized macroscopically (Hochstein and Seligmann, 1979). The test was 
performed in 96-well microtitre plates with serial dilutions of the standard ranging 
from 1 EU to 0.0075 EU and a Sp1 concentration of 5 mg/mL; 25 µL of either 
standard or Sp1 were pipetted per well and after an addition of 25 µL LAL to all wells, 
the plate was incubated for 1 h at 37°C. Endotoxin-free water was used as negative 
control and the serially diluted control standard endotoxin (CSE) from E. coli strain 
055:B5 as positive control and for quantification. Gelation in wells was observed by 
eye. As 3 EU correspond to 1 ng endotoxin, equal gelation levels for standard and 
sample can be used to calculate EU as well as endotoxin levels in 100 µg Sp1. 
 
2.2.2.4 Proton NMR Spectroscopy 
NMR spectra were obtained from a sample of 700 µg of lyophilized purified Sp1- or 
modified Sp1-containing samples, which were reconstituted in 700 µL of D2O. NMR 
experiments were performed on a Bruker DRX500 instrument with a proton 
resonance frequency of 500.13 MHz. The 1H spectra were recorded at 80°C using 
pre-saturation to suppress the water signal. Chemical shifts were referenced in 
relation to 1H2HO resonance at 4.36 ppm. 
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2.2.3 Oxidation, labelling and modification of Sp1  
 
2.2.3.1 Oxidation of Sp1 
Sp1 is a linear polymer of an average molecular size of 70 kDa corresponding to 130 
trisaccharide repeating units with a respective molecular size of 537 Da. Each 
repeating unit of Sp1 contains one positive and two negative charge groups on 
galacturonic acid residues [GalA, residues a and c] and 2-acetamido-4-amino-2,4-6-
trideoxygalactose [Aat, residue b] with a sequence of  3)-a-D-GalA (a)-(1 3)-a-D-
Aat (b)-(1 4)-a-D-GalA (c)-(1  (Tzianabos et al., 1993, Choi et al., 2002, Lindberg 
et al. 1980) (Fig. 1.1). Sp1 was reconstituted in water. For fluorescence labelling of 
Sp1, the adjacent hydroxyl groups on residue c (MW 175 g/mol) were oxidized by 
0.01 M sodium-m-periodate for 90 min in the dark to create highly reactive aldehyde 
functional groups. Reaction was stopped by addition of ethylene glycol and oxidized 
Sp1 was desalted using PD-10 columns, which are pre-packed, disposable gel 
filtration columns. They contain SephadexTM G-25 medium for group separation of 
high (Mr > 5000) from low (Mr < 1000) molecular weight substances and were 
equilibrated with 25 mL water prior to loading. Oxidized Sp1 was loaded to the 
column in a total volume of 2.5 mL and eluted with 3.5 mL water. Subsequently, the 
column was rinsed with 10 mL water and 15 mL NaN3, locking the final 5 mL NaN3 in 
the column till the next use; each column was used 2 to 3 times. Sp1 was lyophilized 
and stored in sterile pyrogen-free glass vials under vacuum till usage or used 
immediately for the labelling experiments.  
 
2.2.3.2 Labelling of oxidized Sp1 by Alexa Fluor® Hydrazide 
The desalted and freeze-dried oxidized Sp1 was weighed and reconstituted in 0.1 M 
sodium acetate buffer (pH 5.5) (22.5 µL sodium acetate buffer/mg Sp1). Lyophilized 
Alexa Fluor® Hydrazide sodium salt was reconstituted in 50 mM potassium 
phosphate solvent buffer (pH 7) to yield a 50 mM Alexa Fluor® dye stock solution. 
Alexa Fluor® Hydrazide was added to Sp1 (2.5 µL Alexa/mg Sp1) and incubated for 
two h at RT in the dark, shaking every 10 min. After incubation, the total volume was 
increased to 2 mL with 0.1 M sodium acetate buffer (pH 5.5) and neutralized with 3 M 
NaOH. The unbound Alexa was separated from the Sp1 solution by passing through 
PD 10 columns twice in the same manner as described above under 2.2.3.1 for 
desalting. Desalted and labelled Sp1 was sterile-filtered, freeze-dried and later 
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weighed, aliquoted and stored as above till usage. The complete labelling protocol 
was performed in the dark. Biological activity of labelled Sp1 was proven by abscess 
induction studies previously.  
 
2.2.3.3 Modification of Sp1 
Modification of Sp1 was conducted by N-acetylation of the free positive amino groups 
on Sp1. Sp1 was dissolved in 1 mg to 10 mg/mL  sodium phosphate buffer (0.1 M) 
and kept on ice under constant stirring which is vital to ensure a good yield of 
acetylation. Acetic anhydride with 5% NaHCO3 was prepared and added at a 10-fold 
molar excess of the amount of amines present in Sp1 to the cold, stirring Sp1 
solution. The addition of the acetic anhydride occurred slowly and in several aliquots 
over a time course of at least 1 h to ensure a good yield of acetylation. Subsequently, 
the actylated Sp1 was purified over a PD10 gel filtration as described in 2.2.3.1, 
sterile-filtered, freeze-dried, aliquoted and used immediately for experiments. 
 
 
2.2.4 Animals 
 
2.2.4.1 Mouse strains 
C57BL/6 mice were obtained from Charles River Laboratories or the Institute for 
Physiology of the University of Cologne and held in the animal facilities of the 
Institute for Medical Microbiology, Immunology and Hygiene. IL-6-deficient mice of 
C57BL/6 background were kindly provided by H. Bluethmann (Hoffmann-LaRoche 
Basel, Switzerland) (Kopf et al., 1994) and held under specific pathogen-free 
conditions at the Institute of Pathology of the University of Cologne. Homozygosity 
was confirmed by PCR. TLR2- and TLR4-deficient mice and MyD88-deficient mice, 
all from C57BL/6 background, were kindly provided by C. Kirschning (TU Munich) 
and the Max-Planck-Institute of Immunobiology in Freiburg, respectively. These 
animals were held at the Institute for Medical Microbiology, Immunology and 
Hygiene. All animals were maintained in an environmentally controlled facility at the 
Medical Microbiology Institute for at least 1 week before experimental abscess 
induction.  
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2.2.4.2 Genotyping of IL-6-deficient mice 
Total DNA was purified (DNeasy Blood & Tissue Kit) from tail biopsies of IL-6-/- mice 
to genotype and ensure their IL-6-deficiency. As control, a tail biopsy of a C57BL/6 
wildtype mouse was used. PCR is a method to amplify specific DNA sequences. The 
DNA or purified water was added along with 10 pmol/µL of the appropriate primers 
(Table 1 in 2.1.12) (Kopf et al. 1994) and purified water to PCR beads (total volume 
25 µL). Each DNA sample was added to two different primer reaction set-ups. 
Reaction 1 contained the forward (IL-6c-pr1) and reverse primer 1 (IL-6c-pr2). 
Reaction 2 contained the forward primer 1 and the reverse primer neo (IL-6-neo). 
The Genotyping PCR protocol was adopted from Jackson Laboratories and the 
thermocycler was programmed as in Tab. 2.2. 
  
TABLE 2.2: IL-6 genotyping PCR protocol 
Step  Temperature Time                       d 
1. Initial denaturation 94°C  3 min 
2. Denaturation 94°C 30 sec 
3. Annealing 61°C 1 min 
4. Elongation 72°C 1 min 
5. Final elongation 72°C 2 min 
 
Steps two to four were repeated 35 times. The final hold was at 10°C.  
An amount of 10 µL of PCR product was electrophoresed on a 1.5% agarose gel 
(+ethidium bromide). The combination of IL-6c-pr1 and IL-6c-pr2 gave a band of 
1314 bp for the IL-6 mutated allele (IL-6-/+ and IL-6-/- mice) and of 174 bp for the wt 
allele. The combination of IL-6c-pr1 and IL-6-neo gave a band of 380 bp for the      
IL-6-/- mutated allele. 
 
 
2.2.5 Abscess induction studies and evaluation of the cellular peritoneal influx 
 
In abscess induction studies, mice were injected intraperitoneally with Sp1 (100 µg of 
Sp1 in PBS mixed with sterile cecal content adjuvant [SCCA]; 1:1 v/v, 0.2 mL total 
volume) (Stephen et al., 2007). SCCA was prepared by mashing the cecal content of 
C57BL/6 mice intestine through a 100 µm sieve with PBS. After autoclaving, the 
                                                                                                   Materials and Methods 
 38
suspension was centrifuged and the supernatant aliquoted and stored at –20°C till 
use. SCCA itself does not induce peritoneal abscesses but mimics peritoneal 
leakage. 
 In order to block IL-6 intraperitoneally, C57BL/6 wildtype mice were injected 
with 250 µg anti-mIL-6 intraperitoneally at the time of challenge and 6 h thereafter. 
Six days after challenge, mice were killed and macroscopically examined for the 
presence of abscesses within the peritoneal cavity by two double-blinded examiners. 
Abscesses were isolated and their diameter was measured before snap-freezing with 
iso-pentane in liquid nitrogen for immunohistochemistry analysis. Only abscesses 
larger than 2 mm were counted as significant. 
 At different time points following intraperitoneal challenge with mod. Sp1, Sp1, 
or Alexa-594-labelled Sp1 (100 µg), WT and IL-6-/- mice underwent peritoneal lavage 
with 2 mL to 4 mL of ice-cold RPMI-1640 supplemented with 10% FBS and 1% 
penicillin/streptomycin to assess secreted cytokines and the cellular influx into the 
peritoneal cavity. A total cell count was performed by trypan blue staining and a 
haemocytometer. Each sample was then analyzed by flow cytometry or fluorescent 
microscopy. In each experiment, three to six mice per group were tested. The 
experiment was performed three times in an independent manner. The studies 
described here were performed in accordance with the guidelines established by the 
German animal protection legislation (legislation number K05/07 for spleen isolation 
and K16.5/06 for iv, sc, ip injections). 
 
 
2.2.6 Isolation of bone marrow-derived DCs and macrophages 
 
BM-derived dendritic cells (BMDCs) were generated from mouse bone marrow by 
adapting a previously described method (Inaba et al., 1992). In brief, bone marrow 
cells from mice were cultured in VLE RPMI 1640 supplemented with 5% FBS, 500 U 
recombinant mouse granulocyte/macrophage-colony stimulating factor (GM-CSF), 20 
µg/mL gentamycin, and 50 µM 2-mercaptoethanol. DC medium was exchanged in 
two-day intervals. DCs were isolated by magnetic cell sorting with a CD11c-specific 
monoclonal antibody (mAb). 
 Bone-marrow (BM)-derived macrophages were generated from C57BL/6 (WT) 
mice as previously described (Inaba et al., 1992). Erythrocytes were lysed with 0.2% 
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and 1.6% saline. After washing, cells were cultured in VLE-RPMI 1640 medium  
supplemented with 10% FBS, 15% L929 supplement, 100 µg/mL 
penicillin/streptomycin, 2 mM glutamine, 2.383 g/L  Hepes, and 0.11 mg/mL sodium 
pyruvate. An equal amount of fresh macrophage medium was added to the medium 
on day 6. Cells were used for experiments on days 10 or 11. 
 
 
2.2.7 Cytokine detection by Multiplex bead assay and IL-6 ELISA 
 
The multiplex fluorescent bead immunoassay (Bender MedSystems) was performed 
to quantify proinflammatory cytokines in the peritoneal fluid at different time points 
following Sp1 challenge or SCCA alone (control). Cells were removed from the 
lavage fluid by centrifugation. The standard, bead mixture, biotin-conjugate mixture 
and streptavidin-PE solution were prepared according to the manufacturer’s manual. 
Wells were pre-wetted with the provided assay buffer, before standard dilutions and 
samples were added. The protocol was used as suggested by the manufacturer and 
the samples were analysed by flow cytometry and the Flow Cytomix Software. 
   BMDCs were stimulated with different Sp1 concentrations (20 µg to 100 µg) at 
different time intervals. Cells were harvested, centrifuged and the supernatant 
collected. The murine IL-6 ELISA was performed as instructed by the manufacturer 
(Diaclone) and absorption was read in the Dyna Tech MR5000 ELISA plate reader at 
450 nm (reference wavelength 620 nm). 
 
 
2.2.8 Flow cytometry  
 
For surface marker staining, lavage cells were stained with specific antibodies for 30 
min on ice, washed, and then analyzed by flow cytometry. For intracellular cytokine 
staining (ICS), the lavage cells were incubated with Fc block for 15 min at 4°C and 
ICS performed according to the manufacturer’s protocol. In brief, cells were stained 
for surface markers for 30 min on ice with specific antibodies, washed, fixed with 
Cytofix/Cytoperm for 20 min on ice. Subsequently, cells were washed and 
permeabilized with Perm/Wash Solution (1:9) and stained with interleukin-specific  
antibodies for 30 min at 4°C.   
                                                                                                   Materials and Methods 
 40
Cells prepared for flow cytometry were analyzed – after gating for viable cells by 
forward and sideward scatter - by FACScan™ using CELLQuest™ software. The 
results were expressed as percentage (%) of fluorescence-labelled cells in a 
population. Experiments were performed a minimum of three times in an independent 
manner. 
 
 
2.2.9 Fluorescence microscopy 
 
To investigate the Sp1-uptake and IL-6 production within Sp1-positive APCs, 
fluorescence and confocal microscopy were performed. After the surface marker 
staining and ICS, cells were transferred onto poly-D-lysine-pre-coated 1.5 cover slips 
attached to 35 mm dishes and then fixed in Cytofix solution (BD). Cells were kept on 
ice until further observation under the confocal microscope. 
 
 
2.2.10 Immunohistochemistry 
 
Snap-frozen abscesses were cryo-sectioned (5-6 µm), fixed in 4% buffered formalin 
for 1 min and then used for immunohistochemical analyses. To determine the IL-6 
secretion of macrophages present in the abscess capsule, a co-staining for IL-6 and 
macrophages was performed, consecutively. After blocking of endogenous 
peroxidase by 0.3% H2O2 in methanol and endogenous biotin by the avidin-biotin 
blocking kit each for 30 min, sections were treated with normal goat serum, and then 
incubated with anti-IL-6 antibody solution (1:50) overnight. Next, an incubation with 
goat AP-conjugated anti-rat antibodies (1 h at RT) and development with Fast Red 
for 30 min followed. Subsequently, macrophages were stained by incubation with 
biotin-linked anti-F4/80 rat anti-mouse antibodies (1:100) for 1 h and a further 
treatment (1 h) with streptavidin-conjugated HRP that was then envisioned with DAB 
substrate. Sections were counterstained with hemalaun. DCs were visualized with 
purified anti-mouse CD11c hamster IgG and goat anti-hamster IgG:Biotin. 
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2.2.11 Apoptosis assay 
 
To test the effect of Sp1 on apoptosis of CD4+ T cells, spleen cells from C57BL/6 WT 
and IL-6-deficient mice (Kopf et al., 1994) were isolated by grinding the tissues 
through a 70 µm mesh. Erythrocytes were lysed (0.2% saline for 30 sec), cells were 
washed and incubated at 1 x 106 cells/mL in starvation buffer or non-starvation buffer 
(RPMI-1640 supplemented with 5% FCS) for 12 h in the presence of chemically 
modified Sp1 (100 µg/mL), Sp1 (100 µg/mL), or in medium alone. The cells were 
then stained with an APC-conjugated anti-CD4 mAb, or its appropriate isotype 
control, for 20 min on ice. After washing, cells were dissolved in binding buffer and 
stained with FITC-conjugated Annexin V (5 µl/1x106 cells) for 15 min on ice. Cells 
were washed, and 5 µl propidium iodide (PI) was added to the cells for 2 min. The PI 
staining was stopped by the addition of 5 mL of ice-cold PBS. Cells were washed and 
prepared for flow cytometry.  
 
 
2.2.12 Quantification of CD4+ T cells in blood, spleen, and peritoneal lavage 
 
Quantification of the CD4+ T cells in blood, spleen, and peritoneal lavage of C57BL/6 
WT and IL-6-deficient mice was performed 24 h following Sp1 challenge. Lavage 
cells were isolated as described above (2.2.5). Spleen cells were isolated by grinding 
the tissues through a 70 µm mesh. Blood was collected in 50 µL Heparin (1:1000 in 
PBS) to prevent clotting. Erythrocytes in blood and spleen samples were lysed (0.2% 
NaCl for 30 sec, 1.6% NaCl), the cells washed, stained with trypan blue, and counted 
with a haemocytometer. The cells were then stained with an anti-CD4 or anti-CD8 
mAb and its appropriate isotype control, and analysed by flow cytometry.  
 
 
2.2.13 Migration assay 
 
CD4+ T cells were purified with the MACS-kit and incubated overnight in RPMI 
medium containing 5% FBS and 1% penicillin/streptomycin. The next day, cells were 
harvested, washed in PBS with 0.1% FBS (buffer) and taken up in 2 mL volume. 
Cells were incubated with the fluorescent dye calcein (6 µL calcein/mL cells) for 20 
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min at 37°C and washed twice thereafter with buffer.  After cell counting, cells were 
adjusted to 5 x 106 cells/mL in degassed buffer. Chemoattractant dilutions of different 
IL-6 concentrations (50 ng to 200 ng/mL) were prepared in buffer and then carefully, 
pipetted onto the bottom plate (29 µL/well). The filter was gently stacked onto the 
bottom plate before 25 µL of cell suspension (1.3 x 105 CD4+ T cells/well) were 
pipetted onto the filter. SLC (secondary lymphoid-tissue chemokine; 500 ng/mL final 
conc.) was used as positive and buffer as negative control.  
 Cell migration through the 5 µm filter to the bottom chamber at 37°C was 
assessed 4 h later. The filter was washed and dried gently with Q tipps. Migration of 
the fluorescent CD4+ T cell from filter to bottom plate was quantified in the Wallac 
Victor by reading plate as well as filter with the Wallac Manager software. Each 
concentration was pipetted in sextets and the migration assay was performed at least 
three times.  
 
 
2.2.14 Nuclear extraction and NFκB ELISA 
 
BMDCs and BM-derived macrophages were treated with Sp1, modified Sp1, and with 
the known TLR ligands LPS (1 µg/mL),  Pam3CSK4 (0.5 µg/mL), Poly I:C (1 µg/mL), 
Flagellin (0.05 µg/mL), Gardiquimod (0.5 µg/mL) and ODN (2 µM/mL) for different 
time intervals. Cells were washed with PBS, scraped, pooled, washed and cell 
counted, centrifuged and taken up in 1 mL PBS. For the preparation of nuclear 
extracts, the cells were resuspended in 400 µL low salt buffer A and incubated 15 
min on ice to allow the nuclei to swell. An amount of 50 µL 10% NP-40 was added 
under shaking to gently lyse the cell leaving the nuclei intact. After sedimenting the 
nuclei, 70 µL of the high salt buffer C was added slowly. The nucleoplasm was 
extracted into the buffer while the nuclear envelop stayed intact and retained the 
genomic DNA. The extract was separated from the nuclear envelop/DNA by 
centrifugation at 13,000 rpm for at least 8 min. A BCA assay (see 2.2.2.2) was 
performed to determine the protein concentration. NFκB ELISA was performed 
according to manufacturer’s instructions. An amount of around 16 µg protein were 
used. Each experiment was repeated at least three times. 
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2.2.15 Whole cell extraction, SDS-PAGE and Western blot 
 
Peritoneal macrophages were starved for 4 h in FBS-free culture medium and then 
treated with Sp1 (100 µg/mL), LPS (1 µg/mL) or Sp1 plus LPS for different time 
intervals. Cells were washed with PBS, scraped, and spun down. Pellets were lysed 
for whole cell extraction in RIPA buffer plus inhibitors and incubated on ice for 30 
min. Cells were centrifuged, the supernatant was collected and used for protein 
determination (see 2.2.2.2) prior to protein sample separation on a SDS-PAGE.  
Protein samples were mixed with loading dye and degraded at 95°C for 5 min. After a 
quick spin, at least 10 µg/mL of protein were transferred to the SDS gel consisting of 
a 10% resolving gel and a 5% stacking gel. The proteins were electrophoresed in a 
blot chamber for 60 min to 90 min at 100 V.  
    An Immobilon-pSQ transfer membrane was pre-wetted in methanol for 5 sec 
before equilibration in transfer buffer for at least 10 min. The proteins were 
transferred from the SDS gel onto the membrane using a semi-dry transfer cell at 20 
V for 45 min. 
    After protein transfer, the membrane was washed in washing buffer for 5 min 
at RT and then treated in blocking solution for 1 h. The membrane was rinsed once 
after blocking with washing buffer and incubated with a Phospho/IκB-α specific 
antibody overnight at 4°C. After four washing steps with washing buffer, 10 min each, 
the secondary HRP-linked antibody was added for 45 min at RT. Three washes for 
10 min each followed. Detection was performed by incubation and rotation with the 
chemiluminescence solution for 5 min. The membrane was developed by exposure to 
a X-ray film for 5 min, 10 min and 15 min.  
    For reprobing the membrane with total-IκB-α and α-tubulin specific antibodies, 
the membrane was stripped. For stripping, the membrane was washed 5 min with 
water, incubated for 5 min at RT with 0.2 M NaOH and washed twice with water for 5 
min each. Membranes were treated again for 20 min with blocking buffer and then 
incubated with total-IκB-α specific antibody overnight at 4°C or α-tubulin specific 
antibody for 2 h at RT. The second antibody incubation and washes were performed 
as described. 
 
 
 
                                                                                                   Materials and Methods 
 44
2.2.16 TLR surface expression and blocking experiments 
 
Human monocytes or BMDCs (4 x 106 cells/mL in 24-well plate) were incubated in 
culture medium alone, or in culture medium containing Sp1 (50 µg/mL) for 8 h and 
prepared for flow cytometry analysis.  
   For the T cell proliferation assay, T cells were isolated by centrifugation in 
Ficoll-Hypaque gradients and purified with nylon wool and immunomagnetic beads 
(Finberg et al. 1992). The purity of the CD3+ and CD4+CD8- cell populations was 
confirmed by flow cytometry ( 95%). The proliferation assays were performed in 24-
well plate transwells and inserts with a 0.1-µm pore size. The lower compartment 
contained 106 gamma-irradiated mononuclear cells as APCs and the upper 
compartment 5 x 105 CD4+ T cells. The cells were incubated in culture medium 
alone, in culture medium containing Sp1 (50 µg/ml, or in culture medium containing 
Sp1 and a mouse IgG2a isotype control antibody, and azide- and endotoxin-free 
blocking antibodies to TLR2, and TLR4 (each at 10 µg/ml) at 37°C, 5% CO2. The 
antibodies were added 30 min before the antigens. T cell proliferation was 
quantitated by [3H]thymidine incorporation (1 µCi/well) for 6 h. Assays were 
performed at least three times at independent time points. The results were 
expressed as counts per minute (cpm) or stimulation index.  
 
 
2.2.17 Statistical analysis 
 
Results of peritoneal cytokine and cellular influx assays in the various groups were 
compared by Student’s t-test. Comparison of groups with regard to abscess 
formation was made by chi-square analysis.  
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3. Results 
 
 
3.1 Purification of Sp1 
Experiments of this study were performed with the zwitterionic polysaccharide (ZPS) 
Sp1, isolated from the capsule of the gram-positive bacterium Streptococcus 
pneumoniae serotype 1. Sp1 was separated from C-substance, a contaminating cell 
wall polysaccharide, and other contaminating components such as proteins, lipids 
and endotoxins by purification via base treatment, ultrafiltration, and gel filtration 
chromatography (Stephen et al., 2005; Kalka-Moll et al., 2002). Polysaccharide 
containing fractions were detected by appraisal of the refraction index peak. Sp1 
purity was ensured by ruling out protein contamination by the BCA method, nucleic 
acid contamination by measurement of the UV absorbance at 260 nm and LPS 
contamination by the LAL test. In addition, Sp1 was subjected to high-resolution 
proton NMR spectroscopy at 500 MHz (Kalka-Moll et al., 2000). Sp1 was found to 
contain no detectable protein and no detectable nucleic acid. Endotoxin was not 
detectable according to the LAL test with a sensitivity of <8 pg of LPS/mg of Sp1 
(<0.4 pg of LPS/mL of culture medium containing 50 µg of Sp1) which corresponds to 
<0.028 EU/mg of Sp1 (<0.0012 EU/mL of culture medium containing 50 µg of Sp1).  
 
 
3.2 Sp1 modification 
As negative controls, medium, PBS, or modified Sp1 (mSp1) were used in biological 
assays. The positive amino groups as well as the negative carboxyl groups contribute 
together to the zwitterionic charge of Sp1 and its ability to induce a T cell-dependent 
abscess formation (Tzianabos et al., 1993). The removal of the positive charge of the 
amino group altered the zwitterionic charge and yielded a polysaccharide with a net 
negative charge. Modification of Sp1 was attained by N-acetylation of the free amino 
group with acetic anhydride. This treatment resulted in the loss of the free amino 
group on the 2-acetamido-4-amino-2,4,6-trideoxygalactose (see Fig 1.1). mSp1 was 
evaluated by 1H NMR spectroscopy which revealed the successful modification of 
Sp1 (Fig. 3.1).  
 
 
                                                                                                                            Results 
 
46 
 
a) 
 
 
b) 
 
 
FIGURE 3.1: Sp1 is chemically modified by acetic anhydride.  1H NMR spectra 
were recorded at 80 °C of a) native Sp1 and b) mSp1. The chemical shift for each 
proton is shown as parts per million (ppm, x-axis). (H, hydroxyl groups of Sp1 
including carbohydrate rings) 
H 
NHAc 
CH3 
mSp1
 
mSp1
 
H 
CH3 
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The black bar (   H   ) from about 4 ppm to 5.7 ppm indicated the region of hydroxyl 
group signals of the Sp1. A high water signal was suppressed (negative peak at 4.75 
ppm) as it was common practice to yield more pronounced peaks and a plain base 
line. The successful modification of Sp1 was confirmed with the presence of new 
peaks at 1.6 ppm and 2.6 ppm. Those indicated new CH3 groups, which composed 
the mSp1. 
 
 
3.3 Bioactivity of Sp1 and mSp1 
ZPS-mediated abscess formation is a T cell-dependent immune response (Stephen 
et al., 2007; Cobb et al., 2004; Kalka-Moll et al., 2002). Figure 3.2 a) shows a typical 
abscess on day 6 after intraperitoneal Sp1 challenge. Modified ZPS had been shown 
to abrogate the ability of abscess formation and CD4+ T cell activation (Tzianabos, 
1993). Bioactivity of Sp1 as well as of mSp1 was tested by intraperitoneal challenge 
with sterile cecal content adjuvant (SCCA) alone or plus Sp1 or mSp1. Six days after 
challenge, mice were opened and examined for abscesses. SCCA that mimics the 
leakage of intestinal flora into the peritoneal cavity did not result in abscess formation 
(Fig. 3.2 b)). SCCA plus mSp1-challenged mice did not form any abscesses whereas 
SCCA plus Sp1-challenged C57BL/6 mice showed a significant increase in abscess 
formation (p<0.05). The ability of purified Sp1 to induce abscess formation confirmed 
its bioactivity. The abrogated bioactivity of mSp1 proved it to be a negative control in 
further experiments. 
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would have indicated the heterozygosity (+/-) of the IL-6KO mice which was not the 
case for the mice used in this study (Fig. 3.3). 
 
 
 
        
 
 
 
 
 
 
 
 
FIGURE 3.3: Tail biopsy genotyping of IL-6KO mice confirmed homozygosity. 
The total DNA was isolated, amplified by PCR and analysed by gel electrophoresis. 
Each of the IL-6KO mice 1, 3, 5, 6, 7, 9 and 10 has two lanes in the above figure, one 
for each reaction. The IL-6KO mice were shown to be homozygous KO mice with a 
1314 bp band in reaction 1 (lane 1) and a 380 bp band in reaction 2 (lane 2); 
negative control (NC): water, positive control (PC): WT mice. 
 
 
3.5 Intraperitoneal Sp1-induced cytokines in abscess formation  
Cytokines known to be involved in T cell activation and proliferation include TNF-α, 
IL-1 and IL-6 among other (Banchereau et al., 2000). IL-1 and TNF-α have been 
demonstrated to play a pivotal role in B. fragilis- and PSA1-induced abscess 
formation in rats (Gibson et al., 1996; Gibson et al., 1998).  
 However, the cytokines involved in Sp1-induced peritoneal abscess formation 
and their further role in this immune response were barely investigated so far. In this 
study, the known pre-dominant pro-inflammatory cytokines IL-1, TNF-α and IL-6 were 
tested in a murine model for their involvement in ZPS-induced intraperitoneal 
abscess formation with Sp1 as the model antigen. IL-6 was demonstrated as the 
predominant cytokine (Fig. 3.4). Six h after Sp1 plus adjuvant challenge, IL-6 
secretion was significantly higher than after SCCA alone challenge (p<0.05).  
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other granulocytes make up the major component of the pus in the abscess center 
(Janeway et al., 2005). Macrophages constitute - as in a septic abscess - a main part 
of the wall of an experimental abscess (Tzianabos and Kasper, 2002). IL-6 is 
produced in large quantities by peritoneal host cells in response to Sp1. To identify a 
cellular source of IL-6 secretion and pivotal IL-6-mediated functions in the process of 
abscess formation, the effect of intraperitoneal Sp1 challenge on macrophages was 
addressed. CD11b-positive macrophages migrated into the peritoneal cavity upon 
Sp1 challenge (Fig. 3.5). Macrophages represent 50% of incoming cells six h after 
Sp1 challenge. SCCA alone (negative control) attracted significantly less 
macrophages and total cells into the peritoneum (*, p<0.05).  
 
      
            
FIGURE 3.5: Influx of total cells and macrophages into the peritoneum upon 
Sp1 challenge. Mice were i.p. challenged with either Sp1 (red symbols) or SCCA 
controls (white symbols). Influx of total cells (square) and CD11b-positive 
macrophages (triangles) into the peritoneum was measured in WT mice (six per 
group). The peritoneal lavage was performed at different time intervals (x-axis) after 
challenge. Cell numbers were determined by cell counting and flow cytometry. Bars 
indicate standard errors within a group tested (p<0.05). 
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Twenty-four h after intraperitoneal Sp1 challenge, about 28% of cells attracted into 
the peritoneal cavity were CD11b macrophages (Fig. 3.6).  
 
 
 
 
 
 
           
 
 
FIGURE 3.6: Sp1-induced macrophage influx into the peritoneum. Lavage cells 
were isolated 24 h after intraperitoneal Sp1 challenge. Macrophages (Mac) of the 
peritoneal influx were stained with PE-conjugated anti-CD11b mAb and analyzed by 
FACS. Numbers in the right dot plot represent the percentage of positive 
macrophages, gated as indicated in the left dot plot and non-gated cells, respectively. 
 
 
Macrophages are known to internalize extracellular antigens by pinocytosis, 
phagocytosis or endocytosis. Therefore, the next step was to examine whether the 
peritoneal macrophages internalize Sp1. Fluorescence microscopy revealed that 
fluorescence-labelled Sp1 was internalized by about 90% of peritoneal macrophages 
(Fig. 3.7). 
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FIGURE 3.7: Peritoneal macrophages internalize Sp1. Mice were challenged 
intraperitoneally with Sp1-Alexa 594 (100 µg). Twenty-four h after Sp1 challenge, 
lavage cells were isolated and stained with CD11b-FITC (green) and analyzed by 
fluorescent microscopy. Scale bar: 10 µm. 
 
 
BM-derived macrophages were also treated with Sp1-Alexa594. Confocal 
microscopy of 100 CD11b+ macrophages revealed that 92% of in vitro macrophages 
internalized Sp1 (Fig. 3.8). 
 
 
       
 
FIGURE 3.8: BM-derived macrophages internalize Sp1. BM-derived macrophages 
were treated with Sp1-Alexa594 (red) for 24 h, stained with the surface marker 
CD11b-FITC (green) and then analyzed under the confocal microscope. The 
merged image visualized the Sp1-Alexa594 uptake in CD11b+ macrophages. The 
experiment was performed four times in an independent manner. Scale bar: 10 µm. 
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FIGURE 3.10: IL-6 secretion by Sp1-positive macrophages. Six h after 
intraperitoneal SCC or Sp1 challenge, macrophages (Mac) of the peritoneal influx 
were surface-stained with PE-conjugated anti-CD11b mAb, and intracellularly with 
FITC-conjugated anti-IL-6, and then analyzed by flow cytometry. Numbers in the 
quadrants of the dot blot represent the percentage of positive macrophages. 
 
 
Macrophages represent the principal constituent of the abscess wall (Tzianabos and 
Kasper, 2002). Intraperitoneal abscesses were isolated six days after Sp1 challenge 
and analysed immunohistochemically. Immunohistochemical analyses of abscesses 
demonstrated incorporation of IL-6-positive macrophages in the wall (Fig. 3.11). 
Taken together, this result demonstrated that IL-6 secreted by macrophages was a 
predominant cytokine in Sp1-mediated abscess formation. 
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FIGURE 3.12: BM-derived DCs internalize Sp1. BM-derived DCs were stained with 
CD11c-FITC (green) after 24 h treatment with Sp1-Alexa594 (red) and analyzed 
under the confocal microscope. The merged image visualized the Sp1 uptake in 
CD11c-positive DCs. The experiment was performed at least five times in an 
independent manner. Scale bar: 10 µm. 
 
 
To investigate whether Sp1-internalized BM-derived DCs secrete IL-6, an ICS was 
performed. Hundred DCs positive for intracellular Sp1 were counted. ICS of Sp1-
Alexa594-treated DCs demonstrated that about 98% Sp1-containing DCs 
accumulated IL-6 (minimum 97%, maximum 98% in three experiments performed 
independently). IL-6 production inside Sp1-positive BM-derived DCs was revealed by 
confocal microscopy (Fig. 3.13).  
 
 
       
FIGURE 3.13: IL-6 production in Sp1-internalized DCs. BM-derived DCs were 
treated for 33 h with Sp1-Alexa 594 (red). Sp1-positive BM-derived DCs were 
analysed for intracellular IL-6 accumulation (FITC, green) by confocal microscopy. 
The merge image visualized Sp1-positive DCs to produce IL-6. Scale bar: 10 µm. 
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FIGURE 3.15: IL-6 secreting DCs localize within abscess capsule. Six days after 
Sp1 challenge, cryo-sectioned intraperitoneal abscesses were stained with a CD11c-
specific antibody to stain DCs (brown) and anti-IL-6 (red), and analyzed by light 
microscopy (20x). The white arrows indicate the CD11c-positive and IL-6-positive 
cells. 
 
 
3.8 IL-6 dose-dependent CD4+ T cell migration 
IL-6 was reported to be a direct mediator of T cell migration. The IL-6-dependent 
migration was demonstrated for primary human T cells and human T cell lines 
(Weissenbach et al., 2004). To test the hypothesis of IL-6-dependent migration for 
murine T cells, a migration assay was performed. Within 4 h, CD4+ T cells isolated 
from spleens of WT mice migrated through a transwell with a 5 µm pore size towards 
IL-6 in a dose-dependent manner (Fig. 3.16).  
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FIGURE 3.16: IL-6 dose-dependent CD4+ T cell migration. Purified CD4+ T cells 
(1.3 x 105 cells in 25 µL / well) from murine splenocytes migrated in an IL-6-dose-
dependent manner through 5 µm filters. IL-6 concentrations (red bars) were prepared 
in buffer (PBS + 0.1% BSA). SLC (secondary lymphoid-tissue chemokine, 500 
ng/mL, black  bar) was used as positive control and buffer (white bar) as negative 
control. The experiments were performed three times in an independent manner and 
each concentration was pipetted in sextets per experiment.  
 
 
3.9 Sp1-induced peritoneal CD4+ T cell influx depends on IL-6 
Abscess formation depends on CD4+ T cell migrating into the peritoneal cavity 
(Tzianabos et al., 2000b). IL-6 has been described as a migration factor for CD4+ T 
cells in different tissues. Therefore, the CD4+ T cell, macrophage and DC cell counts 
in the peritoneal lavage following Sp1 challenge of WT mice were measured, IL-6-
deficient mice, and IL-6-deficient mice treated intraperitoneally with IL-6. As controls, 
cell counts were made from peripheral blood and spleens of WT and IL-6-deficient 
mice. The CD4+ T cell counts in the spleen and peripheral blood of WT and IL-6-
deficient mice were similar (Tab. 3.1). However, compared to WT mice, the peritoneal 
lavage of IL-6-deficient mice showed a 73% decrease in the CD4+ T cell count. The 
peritoneal macrophage cell count was similar in WT and IL-6-deficient mice. The 
number of DCs was reduced in IL-6-deficient mice when compared to WT mice. 
Exogenous IL-6 cytokine treatment of IL-6 KO mice restored the cell count of 
macrophages, DCs, and CD4+ T cells in the peritoneal cavity to levels of WT mice. 
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The results suggest a functional role of IL-6 as a migration factor for CD4+ T cells into 
the peritoneum.  
 
 
TABLE 3.1: T cell counts in C57BL/6 WT and IL-6-deficient mice. C57BL/6 WT 
and IL-6KO mice were challenged intraperitoneally with Sp1 (100 µg) plus SCCA (5 
mice per group). One group of IL-6KO mice were treated intraperitoneally with mouse 
IL-6 (100 µg/kg) at the time of challenge, and at 6 h and 12 h following Sp1 
challenge. Twenty-four h after challenge, cells from C57BL/6 WT and IL-6KO mice 
were isolated from the peritoneum by lavage, and from blood and spleen, stained 
with anti-CD4, and analyzed by flow cytometry. In addition, peritoneal lavage cells 
were stained with anti-CD11b and anti-CD11c antibodies to stain macrophages and 
DCs, respectively. Numbers represent the percentage of cells of the total cells or the 
absolute number. 
 
 Blood Spleen  Peritoneum   
  [%] [%]   [%]  [%]  [%]  [cells x103/ml] 
  CD4 CD4 Mac DC CD4 CD4 
WT          33.6±2.0 21.2±5.8   26.5±13.9 7.3±0.7 4.1±0.4 39.3±3.5 
IL-6KO  35.2± 3.0 18.8±5.9 22.6±5.3 1.7±1.1 1.1±0.1   9.5±0.7 
IL-6KO (+IL-6) n.d. n.d.   28.1±10.1 6.1±2.4 4.3±0.1      41.2±4.0   
 
 
3.10 Anti-apoptotic effect of Sp1-mediated IL-6 secretion on CD4+ T cells 
Sp1 induced CD4+ T cell activation in vitro in a MHC class II- and co-stimulation-
dependent manner (Kalka-Moll et al., 2002, Stephen et al., 2005). IL-6 stimulated the 
activation, survival, and proliferation of CD4+ T cells, acting on T cells as an anti-
apoptotic factor (Takeda et al. 1998; Teague et al., 1997; Van Snick 1990; Lotz et al., 
1988). Whether Sp1 was also capable of protecting CD4+ T cells from apoptosis and 
whether that effect required IL-6 were further questions to investigate. Spleen cells of 
C57BL/6 WT mice were starved to induce apoptosis. CD4+ T cells were purified and 
examined for apoptosis in the presence and absence of Sp1 and chemically modified 
Sp1. As a control, CD4+ T cells were incubated in non-starving medium. 
Fluorescence staining of CD4+ cells with the apoptosis marker annexin V, revealed 
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3.11 Sp1-mediated abscess formation depends on IL-6 
Now, that Sp1 was shown to induce IL-6 in APCs which protected CD4+ T cells from 
apoptosis and lead to T cell migration into the peritoneal cavity, the role of IL-6 in 
Sp1-induced abscess formation was investigated. Peritoneal administration of Sp1 to 
WT mice induced abscesses whereas in IL-6KO mice abscess formation by Sp1 was 
significantly reduced (p<0.05). SCCA alone or challenge with mSp1 (negative 
controls) did not induce abscesses (p<0.05). Furthermore, peritoneal administration 
of an anti-IL-6 neutralizing mAb with the intraperitoneal Sp1 challenge and 6 h 
thereafter resulted in 50% reduction of abscess formation in WT mice (Fig. 3.18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.18: IL-6-dependency of Sp1-mediated T cell-dependent abscess 
formation. C57BL/6 or IL-6KO mice were challenged intraperitoneally with SCCA 
alone or plus mSp1 as controls, or plus Sp1 in the presence or absence of anti-IL-6 
antibody. After 6 days, intraperitoneal abscess formation was examined at autopsy. 
One dot represented the total abscess diameter per mouse; bars indicated the 
median abscess size per group. This figure showed a representative result out of at 
least three experiments performed independently. 
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Altogether, the data so far demonstrated that IL-6 seemed to be required for Sp1-
induced abscess formation. This study showed firstly, that Sp1 challenge lead to 
macrophage and DC influx into the peritoneum. Secondly, these APCs internalized 
Sp1. Thirdly, IL-6 was produced and secreted by Sp1-positive APCs and led fourthly, 
to IL-6-mediated T cell migration. Fifthly, T cell apoptosis was reduced by Sp1-
induced IL-6, and finally Sp1-induced IL-6 secretion lead to a T cell-dependent 
abscess formation in which IL-6-secreting APCs were retrieved in the abscess 
capsule. Next was to identify the pathway of how Sp1 induced IL-6 secretion. 
 
 
3.12 Sp1-mediated NF-κB activation in murine macrophages is impaired 
BM-derived macrophages were treated with Sp1 to test for NF-κB activation. Cells  
were either left untreated or treated with Sp1, LPS, or both for 5 min, 30 min and 60 
min. The whole protein extracts were collected for SDS-PAGE electrophoresis and 
subjected to Western blot using antibodies that recognize IκB-α phosphorylation. 
LPS-treated macrophages showed increased phosphorylated IκB-α levels after 5 min 
whereas extracts of Sp1-treated macrophages showed no increased IκB 
phosphorylation for the different time points tested and remained at similar low levels 
as the non-stimulated cells (Fig. 3.19 a)). A decrease in total IκB-α was observed for 
LPS-treated macrophages after 30 min. Sp1-treated macrophages also showed 
decreased levels of total IκB-α levels after 30 min. After 60 min of LPS or Sp1 –
treatment, total IκB-α levels remained stable or increased, respectively. 
Macrophages treated with both, LPS plus Sp1, decreased constantly in IκB-α levels 
and increased in IκB-α phosphorylation levels with increasing time.  
 In addition, Sp1-induced NF-κB activation in macrophages was tested by 
detecting the translocation of the NF-κB subunit p65 to the nucleus by ELISA. 
Nuclear extracts of BM-derived macrophages were collected after 15 min of either 
mSp1, Sp1 or LPS treatment. NF-κB ELISA did not detect p65-translocation into the 
nucleus of the Sp1-treated WT macrophages and had similar low levels as untreated 
cells or mSp1-treated cells, which were used as controls. In contrast, LPS-treated 
macrophages showed high levels of p65 in the nuclear extracts (Fig. 3.19 b)). 
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3.13 Sp1-mediated NF-κB activation in murine BM-derived DCs 
BM-derived DCs were incubated with various TLR ligands alone or in the presence of 
Sp1 to test for competition to determine possible receptors for Sp1. BM-derived DCs 
treated with Sp1 alone were capable of activating the NF-κB subunit p65 in contrast 
to untreated cells. The TLR2, TLR3, TLR5, TLR7 and TLR9 ligands Pam3, Poly I:C, 
Flagellin, Gardiquimod and ODN, respectively, showed either slight or even no 
difference between the incubation with the ligand alone and co-incubation of ligand 
and Sp1. Interestingly, LPS-treated DCs showed an increased level in p65-
translocation to the nucleus in comparison to LPS plus Sp1-treated cells. The co-
incubation of LPS and Sp1 lead to a 50% decrease in NF-κB activation (Fig. 3.20). 
TLR4 was hence investigated in further detail as potential receptors for Sp1. TLR2 
has been demonstrated to be the receptor for PSA, which upon stimulation activates 
NF-κB (Wang et al., 2006). Therefore, it was of interest to further investigate whether 
TLR2-signalling was induced by other ZPS, like Sp1, too.  
          
FIGURE 3.20: LPS and Sp1 compete for TLR4. BM-derived DCs were incubated 
for 15 min in the presence (red bars) or absence (white bars) of Sp1 with medium 
(Neg) or various TLR ligands: Pam3 (TLR2 ligand), Poly I:C (TLR3 ligand), LPS 
(black bar; TLR4 ligand), Flagellin (TLR5 ligand), Gardiquimod (=Gardiqui., TLR7 
ligand) and ODN (TLR9 ligand). Cells were washed, nuclei extracted and analysed 
for p65-translocation (NF-κB activation) by NF-κB ELISA. 
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3.14 Sp1 induces TLR2 and TLR4 expression in human monocytes 
As TLR2 and particularly TLR4 seemed to be potential Sp1 receptors, the surface 
expression of these two receptors was checked upon Sp1 treatment. In contrast to 
TLR4 surface expression in untreated human monocytes (1.8%), Sp1-treated human 
monocytes showed a TLR4 expression of 26.1%. TLR2 expression increased from 
7.9% in untreated cells to 17.3% in Sp1-treated cells (Fig. 3.21).  
 
 
 
 
 
 
 
 
FIGURE 3.21: Sp1 increase surface expression of TLR2 and TLR4 in human 
monocytes. Human monocytes were treated with Sp1 or medium alone for 8 h and 
analysed by FACS. The results indicate non-stained cells (filled black histogram), 
cells stained with the isotype control IgG2a (black line), with the antibody to TLR2 
(green line), and the antibody to TLR4 (orange line). Percentage of positively stained 
cells are indicated above the marker, for TLR2 (green), for TLR4 (orange). 
 
 
3.15 Sp1-internalization by TLR2KO and TLR4KO DCs  
To test whether DCs of TLR2KO mice and TLR4KO mice were capable of 
internalizing Sp1, BM-derived DCs were treated with fluorescence-labelled Sp1 and 
observed for Sp1 internalization. TLR4KO as well as TLR2KO DCs efficiently 
internalized Sp1, demonstrating that Sp1 uptake was independent from TLR2 or 
TLR4 recognition (Fig. 3.22) and internalized Sp1 like WT DCs as shown in Fig. 3.12. 
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FIGURE 3.22: Sp1 is endocytosed by TLR2KO and TLR4KO DCs. BM-derived 
DCs from a) TLR2KO mice and b) TLR4KO mice were incubated for 24 h with Sp1-
Alexa488 (green) and then stained with an anti-CD11c-PE (red). Scale bar: 10 µm. 
 
 
3.16 Sp1 induces TLR2 and TLR4 expression in WT and KO mice DCs 
As BM-derived DCs of TLR2KO and TLR4KO mice were capable of internalizing 
Sp1, DCs of WT as well as TLR2KO, TLR4KO and MyD88KO mice were investigated 
for TLR2 and TLR4 expression upon Sp1 treatment. MyD88KO DCs were used to 
determine whether Sp1 utilized a MyD88-dependent or MyD88-independent pathway 
to activate NF-κB. Upon Sp1 treatment WT DCs showed a high TLR2 as well as 
TLR4 expression of 12% and 11% respectively. TLR2KO DCs showed upon Sp1 
treatment a low TLR2 expression of 1% and a TLR4 expression of 8%. TLR4KODCs 
upon Sp1 treatment expressed highly TLR2 (8%) and low TLR4 (2%). Interestingly, 
TLR2 as well as TLR4 expression were also impaired in MyD88KO DCs with 1% and 
4% respectively after Sp1 treatment (Fig. 3.23). 
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FIGURE 3.23: Sp1 increase surface expression of TLR2 and TLR4 in murine 
BM-derived DCs. Murine DCs were treated with medium alone (white bars) or Sp1 
(red bars) for 8 h, stained with TLR2 or TLR4 antibodies and analysed by FACS. 
Each experiment was repeated at least three times, except for MyD88KO, which was 
performed once due to limited numbers of mice. 
 
 
So far it was shown that TLR2KO DCs as well as TLR4KO DCs internalize Sp1. It 
was also demonstrated that upon Sp1 uptake, WT DCs expressed TLR2 as well as 
TLR4. Sp1 might induce TLR4 expression in BM-derived DCs in a MyD88-
independent manner.  
 
 
3.17 Sp1-induced cell maturation is mediated by TLR4  
Cell maturation as well as cytokine production can occur in response to TLR 
activation. Maturation of DCs is characterized by the up-regulation of MHC class II 
and co-stimulatory molecules such as CD80 and CD86. Sp1-induced IL-6 production 
and secretion by WT DCs had been demonstrated in this study. To test whether Sp1 
leads to cell surface maturation in APCs, human monocytes were incubated for 8 h 
with medium alone, Sp1 alone, or Sp1 with blocking antibodies. In comparison to 
untreated cells or isotype-treated cells, Sp1-treated human monocytes showed high 
HLA-DR and co-stimulatory surface expression for CD80 and CD86. Treating the 
cells with Sp1 plus isoltype control, anti-CD14 or anti-TLR2 did not lead to 
mentionable differences. However, monocytes treated with Sp1 plus anti-TLR4 
showed a strong decrease for all three tested surface maturation markers (Fig. 3.24). 
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FIGURE 3.25: Anti-TLR4 antibody inhibits Sp1-induced CD4+ T cell proliferation. 
The cells were treated for 6 h with medium alone, Sp1, or Sp1 with monoclonal 
blocking antibodies against TLR2 or TLR4 or the isotype control IgG2α. T cell 
proliferation was quantitated by [3H]thymidine incorporation (1 µCi/well). Mean and 
standard deviation were calculated from three individual experiments. 
 
 
3.19 Sp1-induced NF-κB activation is impaired in TLR4KO DCs  
To explore the appropriate TLR receptor for Sp1 that mediates NF-κB-activation, 
DCs of WT as well as TLR2KO and TLR4KO mice were investigated for NF-κB 
activation after Sp1 treatment. BM-derived DCs were incubated with medium alone 
(untreated) or treated with LPS or Pam3 in the absence and presence of Sp1 and 
investigated for the nuclear translocation of the p65 subunit. MyD88KO DCs were 
treated with medium alone, mSp1, Sp1, LPS, Sp1 and LPS. 
 Sp1-treated WTDCs had an increased p65-translocation level compared to 
untreated WTDCs or mSp1-treated WTDCs, which were used as control. The 
untreated DCs and mSp1-treated DCs of WT as well as KO mice were all at similarly 
low levels. Sp1-induced p65-translocation in TLR2KO DCs was clearly increased and 
had similar levels of p65-translocation as in WTDCs after Sp1 treatment (Fig. 3.26). 
In TLR2KO DCs, NF-κB activation was decreased after treatment with Pam3 alone. 
In contrast, Pam3 plus Sp1-treated DCs were able to activate NF-κB in an almost 
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equal level as after treatments with Sp1 alone or LPS plus Sp1 in TLR2KO DCs. 
Interestingly, Sp1-induced p65-translocation level was 60 % decreased in TLR4KO 
DCs compared to in Sp1-treated WT DCs. Levels of p65-translocation in TLR4KO 
DCs was also decreased after treatment with LPS in the absence and presence of 
Sp1 and at similar low levels as after treatment with Sp1 alone. The levels of NF-κB 
activation after Sp1, LPS and Sp1 plus LPS treatment was either only slightly 
increased or at similar levels of p65-translocation in untreated TLR4KO DCs or 
mSp1-treated MyD88KO DCs, respectively. Treatment with the TLR2 ligand Pam3 in 
absence or presence of Sp1 showed similarly high increased p65-translocation in WT 
DCs as well as TLR4KO DCs. This experiment showed TLR4 as the potential 
receptor for Sp1 in order to activate NF-κB. As Sp1-induced NF-κB activation was 
shown to be impaired in TLR4KO DCs but not in TLR2KO DCs, in the next step, Sp1-
induced IL-6 production was compared between WT and KO mice. 
 
    
FIGURE 3.26: NF-κB activation in WT and KO DCs Sp1 treatment. BM-derived 
DCs from WT, TLR2KO, TLR4KO and MyD88KO mice were treated for 15 min with 
LPS, Pam3, mSp1, or medium alone in the presence of absence of Sp1. Cells were 
washed, nuclei extracted and the p65-translocation was measured with a p65-NF-κB 
ELISA. Mean and standard deviation were calculated from at least three independent 
experiments. 
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3.20 Decreased IL-6 production in Sp1-positive TLR4KO DCs 
DCs of WT, TLR2KO and TLR4KO mice as well as control IL-6KODCs, were treated 
with Sp1 and checked then via ICS for IL-6 production. Sp1-induced IL-6 secretion 
was increased in WTDCs compared to untreated DCs. Sp1-induced IL-6 production 
in IL-6KO DCs was impaired and similar to untreated cells. TLR2KO DCs had an 
Sp1-induced IL-6 production almost as high as in WT DCs (Fig. 3.27). Interestingly, 
IL-6 accumulation was reduced in TLR4KO DCs and showed a similarly low level of 
about 2.7% IL-6-production in CD11c-positive DCs as in IL-6KO DCs. The data so far 
supported TLR4 as an essential Sp1 receptor and therefore TLR4 remained in focus 
for the further experiments. Sp1 could induce NF-κB activation as well as IL-6 
production in TLR2KO DCs and so far showed no impact in Sp1-mediated immune 
responses and was therefore omitted in the next experiments. 
 
 
 
FIGURE 3.27: IL-6 production is impaired in TLR4KO DCs upon Sp1 treatment. 
DCs from WT as well as KO mice were treated with medium alone (white bars) or 
with Sp1 (100 µg / mL, red bars) for 33 h. An ICS was performed with an anti-IL-6- 
FITC murine antibody and DCs were stained with CD11c-(PE)-specific murine 
antibody. DCs were then analysed by FACS for double positive cells. Mean and 
standard deviation were calculated from three individual experiments. 
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3.21 Impaired IL-6 secretion in Sp1-treated TLR4KO DCs 
IL-6 secretion upon Sp1 treatment was tested by IL-6 ELISA. BM-derived WT DCs 
were treated for different time points with Sp1, LPS, and Sp1 plus LPS and the 
culture supernatants were checked for IL-6 secretion after 15 min, 30 min, 60 min, 24 
h and 33 h. The highest IL-6 secretion in WT DCs was detected in this kinetic study 
33 h after Sp1 treatment (Fig. 3.28 a)). The Sp1-induced IL-6 secretion was even 
higher than the LPS-induced IL-6 secretion which was added as control. 
 Then, BM-derived DCs of WT, TLR4KO, IL-6KO and MyD88KO mice were 
treated with Sp1, LPS or both for 33 h and supernatants were measured for IL-6 
secretion by IL-6 ELISA. IL-6KO DCs were taken as control and they showed almost 
no measurable values for IL-6 secretion. Similar results were also obtained for 
TLR4KO DCs treated with Sp1, LPS, both or mSp1 (Fig. 3.28 b)). In WT DCs treated 
with LPS in absence and presence of Sp1, 1125 and 1028 pg/mL IL-6 were secreted, 
respectively. In MyD88KO DCs these values were lower. In MyD88KO DCs, 92 
pg/mL IL-6 were measured after Sp1 treatment compared to 2050 pg/mL IL-6 in Sp1-
treated WT DCs. LPS alone lead to an IL-6 secretion of 98 pg/mL and LPS plus Sp1 
treatment of MyD88KO DCs to 203 pg/mL IL-6. Next to be investigated, was the 
requirement of TLR4 in Sp1-mediated abscess formation. 
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FIGURE 3.28: IL-6 secretion 33 h after Sp1 treatment in WT DCs. a) Kinetics of 
IL-6 secretion of WT DCs treated with medium, Sp1, LPS, LPS plus Sp1 or mSp1 
after 15 min, 30 min, 60 min, 24 h and 33h. IL-6 secretion was measured with an IL-6 
ELISA. b) After 33 h, supernatants of WT, TLR4KO, IL-6KO and MyD88KO DCs 
treated with medium, Sp1, LPS, Sp1 and LPS, or mSp1 were collected and analysed 
by IL-6 ELISA for IL-6 secretion. The experiments were repeated three times in an 
independent manner, except for MyD88KO DCs due to mice shortage. 
 
 
3.22 Sp1-mediated abscess formation is impaired in TLR4KO mice 
Intraperitoneal abscess formation is a complex host response to bacterial infection 
that required several cell types. Activation of CD4+ T cells by ZPS antigens is shown 
to be one essential factor in that process (Chung et al., 2003). In this experiment, it 
was investigated whether the role of CD4+ T cell-dependent process required TLR4.  
WT as well as TLR4KO mice were challenged with SCCA alone as negative control 
or Sp1 plus SCCA. WT mice injected with SCCA alone showed a significantly 
reduced abscess formation compared to WT mice injected with Sp1 plus SCCA 
(p<0.05). All Sp1-challenged WT mice formed abscesses. In contrast to WT mice, 
TLR4KO mice exhibited a significantly reduced ability to form abscesses upon Sp1 
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    p<0.05 
challenge (p<0.05) (Fig. 3.29). Therefore TLR4 was shown to be essential in forming 
Sp1-induced abscesses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.29: TLR4 is required for abscess formation in vivo. WT and TLR4KO 
mice were challenged intraperitoneally with sterile SCCA alone as negative control or 
Sp1 plus SCCA. Six days later, the mice were examined at autopsy for the presence 
of intraabdominal abscess formation. Each dot represents the total abscess size per 
mouse. Bars indicated the median abscess size per group. This figure showed a 
representative result out of at least three experiments performed independently. 
 
 
The obtained results lead to the assumption that Sp1-activated NF-κB-mediated IL-6 
production required TLR4. Sp1 treatment led to impaired NF-κB activation and IL-6 
secretion in TLR4KO and MyD88KO DCs in comparison to WT DCs. Furthermore, 
co-stimulatory maturation molecule expression and CD4+ T cell activation were 
decreased in Sp1-treated cells upon TLR4 blockade. Finally, no abscess formation 
was seen in TLR4KO mice upon Sp1 treatment. 
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4. Discussion 
 
For long polysaccharides were believed to be T cell-independent antigens. Only 
recently, polysaccharides have been shown to elicit CD4+ T cell-dependent immune 
responses due to their zwitterionic charge. ZPS-induced peritoneal abscess 
formation is a CD4+ T cell-dependent immune response and can lead to peritonitis. 
Peritonitis is a life-threatening situation. Hence, it is important to understand the 
underlying mechanisms of ZPS-mediated abscess formation in order to develop 
effective methods of treatment. This study focused on the role of IL-6 in the ZPS-
mediated abscess formation and used Sp1 as a model antigen. 
 
 
4.1 Sp1 is an efficient model antigen for ZPS-induced abscess formation 
For studies on ZPS, various capsular polysaccharides of B. fragilis, S. aureus and S. 
pneumoniae are available (Kalka-Moll et al., 2001, Tzianabos et al., 2001). 
Advantage of using Sp1 is that the capsule-lyophilisate of S. pneumoniae serotype 1 
is commercially available. Besides, if required bacteria can be cultivated in the own 
laboratory under aerobe conditions. Furthermore, purification of ZPS of B. fragilis and 
S. aureus demand complex methods (Moreau et al., 1990). Also, the outer 
membrane of the capsule of B. fragilis, being a gram-negative bacterium, consists of 
LPS. Sp1 is isolated following a modified standardized method (Choi et al., 2002; 
Stephen et al., 2005). The purification procedure excludes a contamination with 
biological active substances by using pyrogen free and sterile materials. Sp1 was 
confirmed to be free of contamination by BCA test, LAL test and UV absorbance as 
well as NMR. The bioactivity of the Sp1 used in the experiments was ensured by 
abscess formation. 
 The removal of the positive charge of the amino group yielded an overall net 
negative charge Sp1. In this study, mSp1 had proven as reliable negative control due 
to its loss of biological activity to induce a CD4+ T cell-dependent abscess formation. 
 
 
4.2 IL-6 is the predominant intraperitoneal Sp1-induced cytokine in abscess formation 
Crohn’s disease is frequently associated with intraperitoneal sepsis and abscess 
formation and interestingly, in contrast to ulcerative colitis, shows higher IL-6 serum 
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concentrations (Van Kemseke et al., 2000; Niederau et al., 1997). The activation of 
the mucosal immune system is characterized by production of proinflammatory 
cytokines (Strober et al., 2002; Blumberg et al., 1999; Fuss et al., 1996). In particular, 
IL-6 and IL-6 signalling appear to play a pivotal role in inflammatory bowel diseases 
(IBDs). IL-6 is produced by APCs and T cells in IBD patients. 
 In this study, we demonstrate the need of IL-6 for the formation of 
polysaccharide-mediated intraperitoneal abscesses. In contrast to experimental 
abscess models in rats using whole B. fragilis and PSA1 as causative agents, Sp1 
challenge in mice induces significantly higher levels of IL-6 than IL-1 and TNF−α 
(Gibson et al., 1996; Gibson et al., 1998). The peak response to the Sp1 challenge of 
IL-6 was at 6 h, of IL-1 at 12 h and of TNF-α at  24 h. In this case, IL-6 was the first of 
the three cytokines to be expressed. Please note that Fig. 3.4 (p. 50) shows a 
logarithmic scale as y-axis and otherwise even the peak values obtained in the 
kinetics for IL-1 and TNF-α would be barely visible compared to the IL-6 values. 
 Several methods and experiments were performed to test other cytokines but 
IL-6. In brief, we have performed TNF-α ELISAs and multiplex bead assays to screen 
for IL-1a, IL-2, IL-5, IL-10, IFN-γ, TNF-α, GM-CSF, IL-4, and IL-17 besides IL-6. 
These experiments did not show a notable increase of the other cytokines. We think 
that the presentation of IL-1, TNF-α, and IL-6 is -although restricted- preferable 
because they are the most important cytokines described so far for secondary 
peritonitis and abscess formation. IL-2 and IL-17 are also cytokines involved in 
abscess formation (Chung et al., 2003, Tzianabos et al., 1999) but as these are 
secreted by the CD4+ T cells, they were not included here because this study clearly 
focuses on the cytokine expression by APCs and not T cells. ZPS such as PSA1, 
PSA2, Sp1 and CP8 have in common the zwitterionic charge motif that contains at 
least one positive and one negative charge per repeating unit (Tzianabos et al., 
2001; 1993). However, for example, PSA1 has exactly one positive charge and one 
negative charge and Sp1 has two negative charges and one positive charge per 
repeating unit. Also, the saccharides and their number per repeating unit differ 
because Sp1 is a trisaccharide whereas PSA is a pentasaccharide. The other studies 
in regard to ZPS-mediated cytokine secretion were performed partly in rats with 
whole ZPS-positive bacteria or ZPS. Consequently, we believe that there are slight 
differences in the mechanism of abscess formation induced by Sp1 and other ZPS. 
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Besides the animal species, the differences include the structural differences, the 
production of cytokines and the signalling pathways (Wang et al., 2006).  
 IL-6 has been recognized as a major participant in elevating the inflammatory 
response in IBD such as Crohn’s disease and ulcerative colitis. Both are severe 
intestinal inflammatory conditions which show increased expression of 
proinflammatory cytokines in inflammed biopsy (Rescigno, 2008; Leon et al., 2006; 
MacDonald and Monteleone, 2005). However, there is evidence suggesting that the 
unaffected tissue areas of IBD undergo an abnormal immune activation as shown by 
the expression of increased levels of the proinflammatory cytokines IL-6, TNF-α 
(Reimund et al., 1996), and IL-18, in intestinal biopsies from Crohn’s disease patients 
(Monteleone et al., 1999). Cytokines are immunomodulators that regulate the 
intensity and duration of the immune response by stimulating or inhibiting the 
activation, proliferation, and differentiation of various cells (Fu, S. Y. et al., 2007).  
 
 
4.3 IL-6 secretion by peritoneal and BM-derived macrophages and BM-derived DCs 
depends on the dose and ZPS charge of Sp1 
Peritoneal as well as BM-derived macrophages and BM-derived DCs were shown in 
this study to internalize Sp1. This is a novelty compared to previous studies which 
showed Sp1 uptake only with human Raji or RJ2.2.5 B cells (Velez et al., 2008).  
 Peritoneal macrophages and DCs, both participating in the formation of the 
abscess wall, secrete IL-6 upon Sp1 treatment. Macrophages are an important 
cellular element, since they reside in the peritoneal cavity and help initiate immune 
responses through phagocytosis and cytokine secretion (Valle et al., 1995). DCs that 
represent a minor population of APCs migrating into the peritoneal cavity upon Sp1 
challenge, are also incorporated into the abscess wall (Stephen et al., 2007). For 
unknown reasons, detection of IL-6 by DCs in vivo is rare. Yet, BM-derived DCs 
secrete IL-6 when treated with Sp1 in vitro. We show in BM-derived DCs in vitro, that 
the induction of IL-6 in DCs clearly depends on the zwitterionic charge motif because 
Sp1 lacking the free amino group and thus resembling a common negatively-charged 
polysaccharide induces a significantly lower IL-6 level. Besides, IL-6 secretion in BM-
derived DCs is Sp1-dose dependent.  
 
 
                                                                                                                  4. Discussion 
 80
4.4 Sp1-mediated IL-6 secretion has migratory and anti-apoptotic effects on CD4+ T 
cells  
In comparison to WT mice, in IL-6-deficient mice the total number of macrophages 
and DCs is decreased by 28% (33.8% of total cells in WT mice and 24.3% of total 
cells in IL-6-deficient mice). However, the number of influx CD4+ T cells is reduced by 
73% in the peritoneal cavity in IL-6-deficient mice. Table 3.1 (p. 61) shows the 
numbers of peritoneal macrophages and DCs in IL-6KO and WT mice. Exogenous 
IL-6 cytokine treatment of IL-6KO mice restored the cell count of macrophages, DCs, 
and CD4+ T cells to levels of WT mice. Besides suggesting a pleiotropic effect of IL-6 
on APCs, the result also identifies IL-6 as a potential CD4+ T cell migration factor in 
the peritoneum. We showed that murine CD4+ T cells migrate into the peritoneum in 
an IL-6-dependent manner. CD4+ T cells migration was increased almost 4 times 
from 50 ng/mL to 200 ng/mL IL-6.  
 Sp1 induces T cell activation and proliferation of mammalian CD4+ T cells in 
vitro and in vivo (Kalka-Moll et al., 2002; Stephen et al., 2007; Velez et al., 2008). 
Activation and proliferation of CD4+ T cells is sustained by IL-2 secretion. Prevention 
of apoptosis through IL-6 has been shown in T cells at different stages of the cell 
cycle (Teague et al., 1997). Testing the effect of Sp1 on apoptosis of CD4+ T cells, 
we observe that Sp1 inhibits their apoptosis. This effect is abrogated when the ZPS is 
converted into a non-ZPS and in the absence of IL-6. This result implies that IL-6 is 
an essential cofactor for the protection from cell death and might indirectly support IL-
2-mediated cellular activation and proliferation in response to ZPS (Tzianabos et al., 
1999; Tzianabos et al. 2000a). 
 
 
4.5 Anti-IL-6 antibodies protect WT mice from Sp1-mediated abscess formation 
The crucial question is whether abrogation of the pleiotropic functions of IL-6 blocks 
abscess formation. Indeed, abscess formation is significantly inhibited in IL-6-
deficient mice. Various options for the prevention and treatment of abscesses are still 
being investigated. For example, in a peritonitis model in rats, treatment with tissue-
type plasminogen and urokinase during the first 24 h after leakage of intestinal 
contents into the peritoneal cavity was very effective in preventing intra-abdominal 
abscess formation (Buyne et al., 2008). Besides the prophylaxis and treatment of 
pathologies with anti-IL-6 monoclonal antibodies that has been shown to be effective 
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against lethal Escherichia coli infection, lethal TNF-α challenge in mice, and Crohn’s 
disease, we see that treatment of mice with a neutralizing IL-6-specific antibody 
reduces abscess formation by 50% (Adachi et al., 2008; Mitsuyama et al., 2006; 
Starnes et al. 1990). As a consequence, early application of an IL-6-specific 
antibody, or targeting of IL-6 signalling, in secondary peritonitis or abdominal surgery 
involving intestinal incisions may offer a prophylactic strategy for the prevention of 
intra-peritoneal abscess formation (Mitsuyama et al., 2006). 
  
 
4.6 Sp1-induced NF-κB activation 
BM-derived macrophages were tested for NF-κB activation after Sp1 treatment. NF-
κB activation was not detected by using total and phosphorylated IκB antibodies and 
subjecting the SDS PAGE to Western blot. In addition, the nuclear translocation of 
NF-κB subunit p65 by NF-κB ELISA did also not show a significant increase after 
Sp1 treatment of macrophages. Sp1-mediated NF-κB activation seemed to utilize 
different mechanisms in BM-derived macrophages than in BM-derived DCs. BM-
derived DCs were used for further investigating Sp1-mediated IL-6 secretion. IL-6 
possess an NF-κB binding site in their promoter regions (Gruss et al., 1992). 
Therefore, in this study it was suspected that the Sp1-induced IL-6 secretion in 
murine DCs may involve TLR-mediated NF-κB activation. DCs treated with various 
TLR ligands in absence and presence of Sp1, showed LPS and Sp1 competing for 
TLR4-mediated NF-κB activation. NF-κB activation was increased after Sp1 
treatment in WT DCs and TLR2KO DCs of this study. TLR4KO DCs and MyD88KO 
DCs, in contrast, showed rather impaired NF-κB activation and IL-6 secretion after 
Sp1 treatment. T cell activation requires TLR-mediated recognition of PAMPs, 
induction of co-stimulation and cell maturation in DCs and production of IL-6 by DCs 
in response to TLR ligation during infection (Pasare and Medzhitov, 2003). The 
special focus was on Sp1-induced NF-κB activation mediated by TLR4. 
 
 
4.7 TLR4-blocking antibodies inhibit Sp1-induced APC maturation and CD4+ T cell 
proliferation  
In APCs cytokines are mainly regulated via TLR signalling (Underhill et al., 1999). In 
recent years, TLRs have emerged as critical to recognise a variety of PAMPs of 
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infectious agents (Akira et al., 2006). In mammalian tissues, TLRs are highly 
expressed by resident immune cells, including DCs and tissue macrophages. Upon 
binding ligands, all known TLRs except for TLR3 can activate downstream signalling 
cascades through the adaptor protein MyD88 to induce the production of 
inflammatory cytokines. These cytokines are interferon-α (IFN-α), IFN-β, IL-12, TNF-
α, IL-6, and IL-1. Especially TLR-activation in DCs induce NF-κB-dependent IL-6 and 
IL-1 production (Kubo et al., 2004). Trif-dependent (MyD88-independent) pathways 
induce NF-κB or IRF-mediated type I IFN production (Tamura et al., 2008; Kawai and 
Akira, 2006). IRF4 has been shown to play a key regulatory role for IL-6 production 
and consecutive activation of T lymphocytes in experimental colitis in mice (Mudter et 
al., 2008).  
 The CD40 ligand interaction on T cells with the CD40 on APCs is critical to 
elevate expression of other co-stimulatory molecules and the secretion of a variety of 
cytokines including IL-6 (Banchereau et al., 2000). It is feasible that the previously 
published requirement of co-stimulatory interactions via B7-CD28 and CD40-CD40L 
for ZPS-dependent CD4+ T cell activation and abscess formation contribute 
significantly to the up-regulation of IL-6 synthesis (Tzianabos et al., 2000b; Stephen 
et al., 2005). 
 In contrast to PSA1 from B. fragilis that causes macrophages and DCs to 
secrete IL-12 and TNF-α in a TLR2-dependent pathway, macrophages and DCs do 
not secrete TNF-α or IL-12 in response to Sp1 (unpublished data and Wang et al., 
2006). Thus, the immune response to the ZPS Sp1 with predominant IL-6 secretion 
seemed to be conferred by another TLR than TLR2. Stimulation of murine 
macrophages with the TLR4 ligand LPS has been shown to induce enhanced cell 
surface antigen expression such as MHCII, CD80 and CD86 as well as IL-6 
production (Ulevitch and Tobias, 1995; Yamamoto et al., 2002). Sp1-treatment also 
induce increased HLA-DR, CD80 as well as CD86 surface display in human 
monocytes (Stephen et al., 2005). Previous experiments revealed Sp1-induced cell 
maturation by increased MHCII, CD80 and CD86 surface display also in murine DCs 
(data not shown). In this study, the TLR responsible for Sp1-mediated APC 
maturation was identified. Human monocytes were treated with Sp1 in absence and 
presence of TLR-blocking antibodies. We showed TLR4 blocking antibodies to inhibit 
Sp1-induced co-stimulatory expression on APCs. Sp1 plus TLR2 blocking antibodies 
showed increased APC maturation as in cells treated with Sp1 alone.  
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 Sp1 is shown to induce T cell-proliferation (Kalka-Moll et al., 2002; Stephen 
et al., 2007; Velez et al., 2008). In this study, Sp1-induced T cell-proliferation was 
inhibited upon the TLR4 blocking antibody application. Blocking antibodies to TLR2 
had no inhibitory effect on APC maturation or T cell proliferation and behaved like the 
cells treated with Sp1 alone affirming the importance of TLR4 in Sp1-mediated CD4+ 
T cell immune responses. 
 
 
4.8 Sp1-induced abscess formation is TLR4-dependent 
We found the Sp1-internalization capabilities of TLR2KO DCs and TLR4KO DCs to 
be similar to the Sp1-internalization by WT DCs. This indicated that the internalization 
of Sp1 was not necessarily receptor-specific. A lack of TLR4 did not inhibit the Sp1 
uptake. Interesting was the TLR4 surface display after Sp1 treatment in MyD88KO 
DCs. The low TLR2 surface display and the increase –though comparably slight- of 
TLR4 surface display in these MyD88KO DCs after Sp1 treatment hinted towards a 
possible involvement of a MyD88-independent pathway. Sp1 is an extracellular 
model antigen. Therefore, an extracellular TLR is required which not only recognizes 
Sp1 but also, based on this result, activates the MyD88-independent pathway. TLR4 
being an extracellular TLR as well as being capable to activate a MyD88-dependent 
as well as MyD88-independent pathway, supports the assumption that TLR4 is a 
possible receptor for Sp1. MyD88-deficient mice lose their ability to produce 
proinflammatory cytokines, such as TNF-α, IL-1, IL-6 and IL-12p40, in response to 
LPS. Albeit with delayed kinetics compared with wild-type cells, DCs of MyD88-
deficient mice can still trigger activation of NF-κB as well as retain their capacity to 
produce IFN-inducible genes and co-stimulatory molecules and to mature in 
response to LPS (Kawai et al., 1999; 2001 and Kaisho et al. 2001). Most other TLRs 
compared to TLR4 are completely ineffective at activating NF-κB in MyD88KO mice 
(Kawai et al., 1999). This indicated that Sp1 might utilize the TLR4 pathway to 
activate NF-κB and produce IL-6.  
 We showed that Sp1 treatment lead to impaired IL-6 production in TLR4KO 
DCs, whereas TLR2KO DCs produced IL-6 at similar levels as WTDCs. In addition, 
this study showed by means of p65-NF-κB-ELISA that the Sp1-induced IL-6 
secretion in TLR4KO DCs is impaired and comparable to the levels of IL-6 secretion 
of IL-6KO DCs. With the abscess formation model, finally, we proved TLR4 to be 
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essential for Sp1-mediated abscess formation. TLR4KO mice showed significantly 
decreased abscess formation in comparison to WT DCs after Sp1 challenge.  
 
 
4.9 Other possible receptors for Sp1-mediated IL-6 secretion 
The immune system is complex and therefore TLR4 might not be the only receptor to 
detect Sp1 to mediate Sp1-induced immune responses. 
Many studies have shown that NOD1 and NOD2 signalling, like TLR signalling, are 
capable of activating NF-κB as well as IL-6 production (Uehara and Takada, 2007; 
Akira et al., 2006; Ogura et al., 2001). NOD1 and NOD2 are intracellular receptors. 
Ex vivo studies showed that S. pneumoniae whole bacteria was sensed by NOD2 
and might mediate NF-κB-dependent cell activation (Opitz et al., 2004). WT DCs 
treated with NOD1 or NOD2 ligands in absence or presence of Sp1 showed, 
however, no difference in the NF-κB activation (data not shown). Sp1 has been 
shown to be transported retrogradually from endosome to lysosomes and then via 
tubuli to the cell surface (Stephen et al., 2007). Therefore, most likely, Sp1 does not 
entertain a direct contact with cytoplasm and NOD1 or NOD2 receptors.  
 Another possible receptor might be DC-SIGN. This C-type lectin receptor is 
present on DCs and has been shown to recognize specifically Streptococcus 
pneumoniae serotypes 3 and 14 (Koppel et al., 2005). Besides functioning as an 
adhesion molecule, a recent study has also shown that DC-SIGN can initiate innate 
immunity by modulating toll-like receptors (den Dunnen et al., 2009). But the detailed 
mechanism is not yet known and an involvement in IL-6 secretion has not been 
demonstrated yet. 
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 4.10 Conclusion and future perspective 
Based on these results we conclude that in peritoneal abscess formation induced by 
the ZPS Sp1, macrophages and DCs recognize ZPS and secrete IL-6. This 
stimulates the IL-6 dose-dependent migration of CD4+ T cells to the peritoneum, and 
inhibits their apoptosis. Peritoneal macrophages, BM-derived macrophages and BM-
derived DCs are capable of internalizing Sp1and thereafter to produce IL-6. Inhibition 
of abscess formation in the absence of IL-6 confirms the biologic importance of this 
innate immune mediator for the cellular adaptive host response. TLR4 is essential for 
Sp1-mediated APC maturation and T cell proliferation. Sp1-mediated NF-κB required 
TLR4. TLR4 has been shown to be essential in Sp1-mediated IL-6 secretion and T 
cell-dependent abscess formation. Therefore, this study shows that Sp1 can induce 
NF-κB-mediated IL-6 secretion and abscess formation via TLR4 signalling. 
Despite many remaining questions, it is clear that TLR regulation of the various 
transcription factors is crucially important in regulating the expression of genes that 
mediate innate and adaptive immunity. This area offers much potential in terms of 
therapeutic exploitation. Recently, TLR9-induced type I IFN has been shown to be 
protective from colitis (Katakura et al., 2005). Such studies and the results obtained 
with the anti-IL-6 antibody treatment to prevent abscess formation and the 
observation that TLR4KO mice do not form abscesses upon Sp1-challenge open up 
further opportunities for therapeutical research.  
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Summary 
 
Abscess formation associated with secondary peritonitis causes severe morbidity and 
can be fatal. Formation of abscesses requires the presence of CD4+ T cells. 
Zwitterionic polysaccharides (ZPS) represent a novel class of immunomodulatory 
bacterial antigens that stimulate CD4+ T cells in a MHC class II-dependent manner. 
The capsular polysaccharide Sp1 of Streptococcus pneumoniae serotype 1 
possesses a zwitterionic charge with free amino groups and promotes T cell-
dependent abscess formation in an experimental mouse model. So far, nothing is 
known about the function of IL-6 in a Sp1-mediated intraperitoneal abscess 
formation. ZPS are only recently been investigated to activate a Toll-like-receptor-
mediated cytokine secretion. To date, a receptor for Sp1 has not yet been 
investigated, which is capable of mediating a Sp1-induced cytokine production. 
In this study, we demonstrated that macrophages and DCs, the most prevalent 
professional antigen-presenting cells (APCs) involved in the formation of abscesses, 
internalize Sp1, secrete IL-6 and are incorporated in the abscess capsule upon Sp1 
challenge in vivo. We found IL-6 secretion to occur in BM-derived DCs in a Sp1 dose-
dependent manner. The Sp1-induced migration of CD4+ T cells into the peritoneal 
cavity requires IL-6 and Sp1 inhibits apoptosis of CD4+ T cells in an IL-6-dependent 
manner. Abrogation of the Sp1-induced pleiotropic effects of IL-6 in IL-6-deficient 
mice and wildtype mice treated with an IL-6-specific neutralizing antibody results in 
significant inhibition of abscess formation.  
We show that Sp1-induced APC maturation and T cell-proliferation are 
inhibited in presence of TLR4 blocking antibodies. Sp1-induced NF-κB activation and 
IL-6 secretion are impaired in in vitro experiments of TLR4-deficient DCs. Sp1-
mediated abscess formation is abrogated in TLR4-deficient mice. Altogether, the data 
shows TLR4 as a possible receptor for Sp1 and delineates the essential role of IL6 in 
the linkage of innate and adaptive immunity in Sp1-mediated abscess formation.  
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Zusammenfassung 
 
Eine Abszessbildung, die mit einer sekundären Peritonitis einhergeht, kann 
schwerwiegenden Krankheitssymptome hervorrufen und fatale Folgen mit sich bringen. 
Damit sich Abszesse bilden können, müssen CD4+ T Zellen vorhanden sein. Außerdem 
sind Makrophagen und DCs (Dendritische Zellen) die am häufigsten in der Entstehung 
von Abszessen vorkommenden professionellen Antigen-präsentierenden Zellen (APZ).  
Bislang besagte das immunologische Dogma der Antigenpräsentation, dass 
Polysaccharide T Zell-unabhängige Immunreaktionen auslösen und nach der 
Internalisierung in den Lysosomen verbleiben. Zwitterionische Polysaccharide (ZPS) 
stellen jedoch eine neuartige Klasse von immunmodulatorischen bakteriellen Antigenen 
dar, welche CD4+ T Zellen in einer MHC Klasse II-abhängigen Art stimulieren. Das 
kapsuläre Polysaccharid Sp1 von Streptococcus pneumoniae Serotyp 1 besitzt eine 
zwitterionische Ladung und kann so die T Zell-abhängige Abszessbildung in einem 
experimentellen Mausmodel begünstigen. Bislang ist über die Funktion von IL-6 in der 
Sp1-induzierten intraperitonealen Abszessbildung nichts bekannt. ZPS wurden erst in 
den letzten Jahren bezüglich einer TLR (Toll-like-receptor) vermittelten 
Zytokinausschüttung erforscht. Hier wurden nun der Zusammenhang von Sp1-
induzierten Abszessen in Abhängigkeit von IL-6 als auch ein geeigneter Rezeptor für 
Sp1 untersucht. 
In dieser Arbeit wird gezeigt, dass APZ in WT (Wildtyp) Mäusen nach Sp1 Gabe 
das Sp1 internalisieren, IL-6 ausschütten und Bestandteile der Abszesskapsel bilden. 
Für die durch Sp1-induzierte Migration von CD4 T+ Zellen in die Peritonealhöhle ist IL-6 
erforderlich. Zusätzlich konnte nachgewiesen werden, dass die Inhibition der CD4+ T 
Zellapoptose durch Sp1 von IL-6 abhängig ist. Die Unterdrückung der Sp1-induzierten 
pleiotropischen Effekte von IL-6 in IL-6 defizienten Mäusen sowie WT Mäusen, die mit 
IL-6-spezifisch neutralisierenden Antikörpern behandelt wurden, resultieren in einer 
signifikanten Inhibition der Abszessbildung.  
Außerdem konnte belegt werden, dass die Sp1-induzierte Reifung von APZ und 
die Proliferation von T Zellen durch TLR4-blockierende Antikörper eingeschränkt wurde. 
Die NF-κB-Aktivierung und IL-6 Ausschüttung durch Sp1 sind in TLR4-defizienten DCs 
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stark eingeschränkt. Überdies konnte in TLR4-defizienten Mäusen keine Sp1-vermittelte 
Abzessbildung nachgewiesen werden.  
Diese Daten beschreiben die essentielle Rolle von IL-6 in der Verknüpfung der 
angeborenen und erworbenen Immunität in der Polysaccharid-vermittelten 
Abszessbildung. Folglich ermutigen die Daten die Erforschung weiterer Therapieansätze 
mittels IL-6 und TLR4 Antikörpern zur Behandlung von ZPS verursachter Peritonitis. 
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List of abbreviations 
 
 
Å Ångström 
Ab Antibody 
AP-1 Adapter-protein-1 
APC Antigen-presenting cell 
APC Allophycocyanine 
APS  Ammonium persulphate 
ATCC American Type Culture Collection 
BCA Bicin choninic acid 
BM Bone-marrow  
bp Base pairs 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CLIP Class II-associated invariant chain peptide 
CP Staphylococcus aureus type capsular polysaccharide 
CpG Cytosine-phosphate-guanine 
cpm Counts per minute 
CSE  Control standard endotoxin 
DC Dendritic cell 
DC-SIGN DC-specific intercellular adhesion molecule-3-Grabbing Non- 
 integrin 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
ds Double stranded 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
e. g. exempli gratia 
EGTA Ethylene glycol bis2-aminoethyl-tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
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EU  endotoxin unit 
FACS  Fluorescent activated cell sorter 
FBS Fetal bovine serum 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FPLC Fast performance liquid chromatography  
FSC Forward scatter 
GMCSF Granulocyte-macrophage colony stimulating factor 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLA Human leukocyte antigen 
HRP Horseradish peroxide 
IBD Inflammatory bowel disease 
ICAM Intercellular adhesion molecule 
ICS Intracellular cytokine staining 
iDC Immature DC 
IFN Interferon 
Ig Immunoglobulin 
IH(C) Immunohistochemistry 
IκB Inhibitory κB 
IKK IκB kinase 
IL Interleukin 
i.p. Intraperitoneal 
IRAK IL-1 receptor-associated kinase 
IRF IFN regulatory factor 
i.v. Intravenous 
JNK c-Jun N-terminal kinase 
kDa Kilo Dalton 
KO Knock-out 
LAL Limulus amoebocyte lysate 
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinase 
MDP Muramyl dipeptide 
MFI Mean fluorescence intensity 
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MHC Major histocompatibility complex 
Mod Modified 
mDC Mature DC 
mSp1 Modified Sp1  
MyD88 Myeloid differentiation primary response protein 88  
NaCl Sodium chloride 
NEMO NF-κB essential modulator 
NF-κB Nuclear factor kappa B 
NLR NOD-like receptor 
NMR Nuclear magnetic resonance 
NO Nitric oxide 
NOD Nucleotide-binding oligomerization domain 
OD Optical density 
PAMP  pathogen-associated molecular pattern  
PBMC Peripheral blood mononuclear cells 
PBS Phospate buffered saline 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PI  Propidium iodide 
PMNL Polymorphonuclear leukocytes  
PRR  Pattern-recognition receptors  
PSA Polysaccharide A from Bacteroides fragilis 
RNA Ribonucleic acids 
s.c. Subcutaneous 
SCCA Sterile cecal content adjuvant 
SDS-PAGE Sodium dodecylsulfate polyacrylamide gel electrophoresis 
Sp1 Capsular polysaccharide from Streptococcus pneumoniae type 1 
ss Single stranded 
SSC Sideward scatter 
TAE Tris-acetate-EDTA-buffer 
TAK1 TGFβ activated proteinkinase 1  
TCR T cell receptor 
TEMED Tetramethylethylenediamine 
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TGFβ Transforming growth factor-β 
Th T helper cell 
TIR  Toll/IL-1 receptor 
TIRAP  TIR domain-containing adapter protein  
TLR Toll-like receptor 
TNF Tumor necrosis factor  
TRAF TNF receptor associated factor 
TRAM Trif-related adapter molecule 
TriDAP Tripeptide L-Ala-D-Glu-mDAP 
Trif  TIR domain-containing adapter inducing IFNβ 
TSST1 Toxic shock syndrome toxin-1  
TT Tetanus toxoid 
UC Ulcerative colitis 
VLE Very low endotoxin 
WB Western blot 
WT Wildtype 
ZPS Zwitterionic polysaccharide 
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ABSTRACT 
Abscess formation associated with secondary peritonitis causes severe morbidity and can be 
fatal. Formation of abscesses requires the presence of CD4+ T cells. Zwitterionic 
polysaccharides (ZPS) represent a novel class of immunomodulatory bacterial antigens that 
stimulate CD4+ T cells in a MHC class II-dependent manner. The capsular polysaccharide 
Sp1 of Streptococcus pneumoniae serotype 1 possesses a zwitterionic charge with free amino 
groups and promotes T cell-dependent abscess formation in an experimental mouse model. So 
far, nothing is known about the function of IL-6 in intraperitoneal abscess formation. Here, 
we demonstrate that macrophages and DCs, the most prevalent professional antigen-
presenting cells involved in the formation of abscesses, secrete IL-6 and are incorporated in 
the abscess capsule. Sp1 inhibits apoptosis of CD4+ T cells and causes IL-17 expression by 
CD4+ T cells in an IL-6-dependent manner. Abrogation of the Sp1-induced pleiotropic effects 
of IL-6 in IL-6-deficient mice and mice treated with an IL-6-specific neutralizing antibody 
results in significant inhibition of abscess formation. The data delineate the essential role of 
IL-6 in the linkage of innate and adaptive immunity in polysaccharide-mediated abscess 
formation.  
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INTRODUCTION 
 
Secondary peritonitis, which is by far the most common form of peritonitis, results from loss 
of integrity in the gastrointestinal tract, leading to contamination of the peritoneal space by 
commensal intestinal bacteria.1 Despite improved diagnostic modalities, potent antibiotics, 
modern intensive care, and aggressive surgical treatment, up to one third of patients still die 
from generalized peritonitis.2 The cornerstones of successful surgical treatment for 
generalized peritonitis are thorough peritoneal lavage, drainage of localised abscesses, 
repairing, which may require removal of the contaminating source, and effective drainage of 
the peritoneal cavity. However, even with optimal therapy including the administration of 
antibiotics, residual abscesses form in many patients, resulting in substantial morbidity and 
mortality.3 
Abscess formation is known to be a T cell-dependent immune response induced by the 
capsular polysaccharide of commensal bacteria.4,5 So far, only protein antigens were believed 
to be capable of inducing direct T cell responses, whereas polysaccharide antigens were said 
to be T cell-independent.6 Indeed, most bacterial polysaccharides usually find their end station 
in lysosomes of antigen-presenting cells (APCs) without further processing or presenting on 
the APC surface to T cells.7 However, in vivo and in vitro studies showed that polysaccharides 
of certain commensal bacteria are transported from lysosomes to the cell surface where they 
are presented by MHC class II to activate CD4+ T cells in vitro and induce CD4+ T cell-
dependent abscesses in vivo.8-10 These polysaccharides such as PSA1 and PSA2, Sp1, and 
CP5 from the bacteria Bacteroides fragilis, Streptococcus pneumoniae serotype 1 and 
Staphylococcus aureus, respectively, are characterized by opposite charge motifs on each 
repeating unit and are therefore called zwitterionic polysaccharides (ZPS).11-16 Elimination of 
their charged groups abrogates T cell-dependent immune responses in vitro and in vivo.5 
Zwitterionic polysaccharides promote intra-abdominal abscess formation and CD4+ T cell 
IL-6 in polysaccharide-mediated abscess formation          Meemboor et al. 
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activation via the co-stimulatory molecules B7-2 and CD40 on activated APCs.17,18 In 
intraperitoneal abscess formation, not only cell activation and co-stimulation but also 
cytokines and adhesion molecules are important. Gibson et al. demonstrated that ZPS PS A1 
induces the production of TNF-α and IL-1α on peritoneal cells which act as significant 
immune mediators for abscess formation.19,20 If TNF-α is blocked, expression of the 
intercellular adhesion molecule 1 (ICAM-1) is significantly reduced so that accumulation of 
polymorphonuclear leukocytes within the abdominal cavity, the hallmark of peritoneal sepsis, 
is inhibited. Furthermore, PS A1 stimulates the secretion of chemokines, such as IL-8, from T 
cells.21 In mice challenged with whole B. fragilis, CD4+ T cells mediate abscess formation by 
an IL-17-dependent mechanism.22 Treatment of mice with an IL-17-neutralizing antibody 
significantly inhibited abscess formation.  
During sepsis and peritonitis, besides the release of cytokines such as TNF-α and IL-1, IL-6 is 
also an important mediator of immunologic alterations in the host.23,24 High titres of IL-6 
result from complex amplification mechanisms involving IL-1 and TNF-α.25-28 Evidence 
suggests that IL-6 is a very potent proinflammatory cytokine because it stimulates the 
expression of the broadest spectrum of acute phase proteins in inflammation and 
infection.29,30. IL-6 a pleiotropic inflammatory cytokine, is produced by a variety of cells and 
acts on a wide range of tissues.31 It stimulates the activation, survival, proliferation of CD4+ T 
cells and acts on T cells as an anti-apoptotic factor.32-35 It prevents apoptosis of normal and 
resting T cells in the absence of additional cytokines. IL-6 has also been identified as a 
migration factor. In vitro experiments showed chemotactic activity of IL-6 on peripheral 
blood lymphocytes, lymphokine-activated killer cells, CD4+, and CD8+ T lymphocytes.36-38 
IL-6 has also been identified as a migration factor for breast cancer cells, corneal epithelial 
cells and keratinocytes, and T cells in vitro.39-44 Additionally, it has been linked to T cell-
IL-6 in polysaccharide-mediated abscess formation          Meemboor et al. 
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dependent immune diseases and autoimmune diseases such as inflammatory bowel disease.45, 
46
  
IL-6 and the transforming growth factor-β (TGF-β) are required for the in vivo and in vitro 
differentiation and function of a distinct subset of proinflammatory CD4+ T cells that produce 
IL-17 (TH-17 cells).47 TH-17 cells are thought necessary for the control of a variety of 
bacterial and fungal infections at mucosal surfaces and have been shown to have critical 
functions in human diseases, including Crohn’s disease.48-51 
So far, nothing is known about the role of IL-6 in ZPS-mediated abscess formation and CD4+ 
T cell responses. Here, we demonstrate that IL-6 plays a critical role in abscess formation. 
Macrophages and DCs secrete IL-6 in response to the ZPS Sp1. Sp1-induced migration of 
CD4+ T cells into the peritoneal cavity, inhibition of CD4+ T cells apoptosis, and IL-17-
expression of CD4+ T cells require IL-6 secretion. Together, this data illustrates the 
requirement of IL-6 secretion by cells of the innate immune system for CD4+ T cell immune 
responses to zwitterionic polysaccharides. 
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MATERIALS AND METHODS 
 
 
Antigens 
S. pneumoniae type 1 capsular polysaccharide complex was obtained from the American Type 
Culture Collection (ATCC) and further purified to obtain homogeneity as previously 
described.10, 18 S. pneumoniae type 1 capsular polysaccharide complex was treated with 2 M 
NaOH for 1 h at 80°C to remove C substance (a contaminating cell wall polysaccharide). 
After purification by gel-permeation chromatography with Sephracyl S-400 HR (Amersham 
Pharmacia Biotech), the Sp1 was concentrated by ultrafiltration and lyophilization and stored 
at a concentration of 1 mg/ml in 0.15 M phosphate-buffered saline. Chemical modification of 
Sp1 by neutralization of the free amino group on the 2-acetamido-4-amino-2,4,6-
trideoxygalactose by N-acetylation that creates a polysaccharide with a net negative charge 
was performed as previously described.5 
The polysaccharide antigen was purified aseptically with sterile water. The instruments and 
devices used in the antigen purification process were deproteinated by treatment with sulfuric 
and chromic acid and depyrogenated by heat inactivation for 4 h at 240°C or by treatment 
with 1 M to 2 M sodium hydroxide buffer. The antigens were analyzed for protein by the 
bicinchoninic acid method (Perbio) and by UV absorbance at 280 nm, for nucleic acid by UV 
absorbance at 260 nm, and for endotoxin (lipopolysaccharide [LPS]) by the limulus 
amebocyte lysate test (Charles River Endosafe). In the limulus test, the antigens were 
evaluated alone and in the presence of LPS; LPS alone served as a positive control. Sp1 was 
found to contain no detectable protein and no detectable nucleic acid. Endotoxin was not 
detectable in the above preparations according to the limulus test with a sensitivity of <8 pg of 
LPS/mg of Sp1 (<0.4 pg of LPS/ml of culture medium containing 50 µg of Sp1) which 
corresponds to <0.028 endotoxin units [EU/mg of Sp1 (<0.0012 EU/ml of culture medium 
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containing 50 µg of Sp1). In addition, the polysaccharide antigen was subjected to high-
resolution (500 MHz) proton nuclear magnetic resonance spectroscopy 15, 52 Fluorescent 
labelling of Sp1 with Alexa-Fluor® 594 (Invitrogen) (Sp1-Alexa 594) was performed as 
previously described.10 LPS (026:B6) was obtained from Sigma. 
 
Abscess induction studies and evaluation of the cellular peritoneal influx 
Animal experiments were performed in accordance with the German animal protection 
legislation guidelines (license number K07/05 and K16.5/06). Homozygous IL-6-deficient 
(IL-6-/-) mice were generously provided by Prof. H. Bluethmann (Basel, Switzerland).53 
Homozygosis was confirmed by PCR. Wildtype mice C57BL/6 were obtained from Charles 
River Laboratories.  
In abscess induction studies, 6-8 week-old C57BL/6 and IL-6-/- mice were injected 
intraperitoneally with Sp1 or modified Sp1 (100 µg in PBS mixed with sterile cecal content 
adjuvant [SCCA]; 1:1 v/v, 0.2 ml total volume) or SCCA alone (as control).10 In order to 
block IL-6 intraperitoneally, C57BL/6 wildtype mice were injected intraperitoneally with 250 
µg of anti-mIL-6 (clone MP520F3, R&D) at the time of challenge and 6 h later. 
At different time points following Sp1 challenge, mice underwent peritoneal lavage with 4 ml 
of ice-cold RPMI-1640 supplemented with 10% FBS and 1% penicillin/streptomycin to 
assess secreted cytokines and the cellular influx into the peritoneal cavity. The cellular influx  
was assessed at different time points following intraperitoneal challenge of WT and IL-6-/- 
mice with modified Sp1, Sp1, or Alexa-594-labelled Sp1 (100 µg). A total cell count was 
performed by trypan blue staining and a haemocytometer. Each sample was then analyzed by 
flow cytometry or fluorescent microscopy. In each experiment, three to six mice per group 
were tested. The experiment was performed three times in an independent manner.  
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Six d after challenge, mice were macroscopically examined for the presence of abscesses 
within the peritoneal cavity by two double-blinded examiners. Abscesses were isolated and 
their diameter was measured. In each experiment, four to six mice per group were tested. The 
experiments were performed three times in an independent manner.  
 
Isolation of bone marrow-derived DCs and macrophages 
DCs were generated from mouse bone marrow by adapting a previously described method.54  
In brief, bone marrow cells from C57BL/6 mice were cultured in RPMI 1640 supplemented 
with 5% FBS, 500 U recombinant mouse granulocyte/macrophage-colony stimulating factor 
(GM-CSF), 20 µg/ml gentamicin, and 50 µM 2-mercaptoethanol. DC medium was exchanged 
in two-day intervals. DCs were isolated by magnetic cell sorting with a CD11c-specific 
monoclonal antibody (mAb) (Miltenyi Biotec).  
Bone-marrow (BM)-derived macrophages were generated from C57BL/6 (WT) mice as 
previously described.54 Erythrocytes were lysed with 0.2% and 1.6% saline. After washing, 
cells were cultured in RPMI medium supplemented with 10% FBS, 15% L929 supplement, 
1% penicillin/streptomycin, 1% glutamine, 1% Hepes, and 1% sodium pyruvate. An equal 
amount of fresh macrophage medium was added to the medium on day 6. Cells were used for 
experiments on d 10 or 11. 
 
Cytokine detection 
The multiplex fluorescent bead immunoassay (Bender MedSystems) was performed to 
quantify proinflammatory cytokines in the peritoneal fluid 6 h following Sp1 challenge or 
SCCA alone (control). Cells were removed from the lavage fluid by centrifugation. The 
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protocol used was as suggested by the manufacturer and the samples were analysed by flow 
cytometry and the Flow Cytomix Pro 1.0 Software BMSFFS/1.0 (Bender MedSystems). 
BM-derived dendrite cells (DCs) were stimulated with different Sp1 concentrations (20 µg to 
100 µg). Cells were harvested, centrifuged and the supernatant collected to measure the IL-6 
secretion via ELISA. The murine IL-6 ELISA was performed as instructed by the 
manufacturer (Diaclone) and absorption was read in the UV/Vis spectrometer at 450 nm 
(Perkin Elmer Lambda 40). 
 
Flow cytometry and intracellular cytokine staining 
For surface marker staining, lavage cells were stained with specific antibodies for 30 min on 
ice, washed, and then analyzed by flow cytometry. For intracellular cytokine staining (ICS), 
lavage cells were stimulated with anti-CD3 (5 ng/ml) and CD28 (500 ng/ml) for 6 h at 37°C 
and 5% CO2. After the first hour of incubation, Golgi Stop (BD Harlingen) was added. Cells 
were stained for surface markers for 30 min on ice with specific antibodies, washed, fixed 
with Cytofix/Cytoperm (BD Pharmingen) for 20 min on ice, and then, permeabilized with 
Perm/Wash Solution (BD Pharmingen). For interleukin staining, cells were treated with 
interleukin-specific antibodies for 30 min at 4°C.   
CD4 (clone RM4-5, BD), CD11b (clone M1/70, BD), CD11c (clone HL3, BD), and the 
respective isotype controls were used for surface marker staining. For ICS, anti-mouse mIL-6 
(MP5-20F3, R&D), IL-17 (TC11-18H10, BD), and the respective isotype controls were used. 
Cells prepared for flow cytometry were analyzed – after gating for viable cells by forward and 
side scatter - by FACScan™ (Becton Dickinson) using CELLQuest™ software (Becton 
Dickinson). The results were expressed as percentage (%) of fluorescent-labelled cells in a 
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population. Experiments were performed a minimum of three times in an independent 
manner. 
 
Fluorescent microscopy 
To investigate the Sp1-uptake and IL-6 production within Sp1-positive APCs, fluorescent 
microscopy was performed. After the surface marker and intracellular cytokine staining, cells 
were transferred on to poly-D-lysine-pre-coated number 1.5 cover slips attached to 35 mm 
dishes (MatTek, USA) and fixed in Cytofix solution (BD). Cells were observed immediately 
under the microscope (Olympus FluoView FV1000 Confocal). 
 
Immunohistochemistry 
Snap-frozen abscesses were cryo-sectioned (5-6 µm), fixed in 4% buffered formalin for 1 min 
and then used for immunohistochemical analyses. To determine the IL-6 secretion of 
macrophages and DCs present in the abscess capsule, a co-staining for IL-6 and cells was 
performed, consecutively. After blocking endogenous peroxidase by 0.3% H2O2 in methanol 
and endogenous biotin by a avidin-biotin blocking kit (Vector Laboratories, Eching, GER) for 
30 min each,  sections were treated with normal goat serum, and then incubated with an anti-
IL-6 antibody (1:50; rat anti-mouse clone MP5-20F3, Biosource) for 18h. Next, incubation 
with a goat alkaline phosphotase-conjugated anti-rat antibody (1 h at 20-22°C) and 
development with Fast Red (Dako, Hamburg) for 30 min were performed. Subsequently, 
macrophages were stained with a biotin-linked anti-F4/80 rat anti-mouse antibody (clone A3-
1; 1:100; Serotec) and a further treatment with streptavidin-conjugated HRP for 1 h. DCs 
were stained with a purified hamster anti-mouse CD11c (clone HL3, BD), biotinylated goat 
anti-hamster IgG (STAR79B, Serotec), and further treatment with streptavidin-conjugated 
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HRP for 1 h. The staining was envisioned with DAB substrate (Vector Laboratories). Sections 
were counterstained with hemalaun.    
 
Apoptosis assay 
To test the effect of Sp1 on apoptosis of CD4+ T cells, spleen cells from C57BL/6 WT 
(Charles River Laboratories) and IL-6-deficient mice were isolated by grinding the tissues 
through a 70 µm mesh. Erythrocytes were lysed (0.2% saline for 30 sec), cells were washed 
and incubated at 1 x 106 cells/ml in starvation buffer (RPMI-1640 supplemented with 0.1% 
FCS) or non-starvation buffer (RPMI-1640 supplemented with 5% FCS) for 12 h in the 
presence of chemically modified Sp1 (100 µg/ml), Sp1 (100 µg/ml), or in medium alone. The 
cells were then stained with an APC-conjugated anti-CD4 mAb (clone RM4-5, BD), or its 
appropriate isotype control, for 20 min on ice. After washing, cells were dissolved in binding 
buffer (0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 25 mM CaCl (BD)) and stained with 
FITC-conjugated Annexin V (5µl/1x106 cells; BD Apoptosis Detection Kit) for 15 min on ice. 
Cells were washed, and 5µl propiumiodide (PI) (BD) was added to the cells for 2 min. The PI 
staining was stopped by the addition of 5 ml of ice-cold PBS. Cells were washed and prepared 
for flow cytometry.  
 
Quantifying CD4+ T cells in blood, spleen, and peritoneal lavage 
Quantifying the CD4+ T cells in blood, spleen, and peritoneal lavage of C57BL/6 WT and IL-
6-deficient mice was performed 24 h following Sp1 challenge. Spleen cells were isolated by 
grinding the tissues through a 70 µm mesh. Erythrocytes in blood and spleen samples were 
lysed (0.2% saline for 30 sec), the cells washed, stained with trypan blue, and counted with a 
haemocytometer. The cells were then stained with an anti-CD4 mAb (clone RM4-5, BD) and 
its appropriate isotype control, and analysed by flow cytometry.  
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Statistical analysis 
Results of peritoneal cytokine and cellular influx assays in the various groups were compared 
by Student’s t-test. Comparison of groups with regard to abscess formation was made by chi-
square analysis.  
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RESULTS 
 
Peritoneal Sp1-induced cytokines in abscess formation   
IL-1 and TNF-α have been described as essential mediators of B. fragilis- and PS A1-induced 
abscess formation in rats.19, 20 Here, we tested the cytokines IL-1, TNF-α, and IL-6 for their 
involvement in ZPS-induced intraperitoneal abscess formation with Sp1 as the model antigen 
in a murine model. We demonstrate IL-6 as the predominant cytokine (Fig. 1). In contrast to 
the sterile cecal content adjuvant (SCCA) alone, which is used as a control to mimic the 
leakage of intestinal flora into the peritoneal cavity and does not result in abscess formation 
10
, Sp1 plus adjuvant induces significantly higher secretion of IL-6 that peaks at 6 h following 
Sp1 challenge (p<0.05). Interestingly, IL-1 and TNF-α are detected at significantly lower 
levels after Sp1 challenge than IL-6 (p<0.05). 
 
 
Sp1 induces IL-6 secretion by peritoneal macrophages  
IL-6 is produced in large quantities by peritoneal host cells in response to Sp1. To identify a 
cellular source of IL-6 secretion and pivotal IL-6-mediated functions in the process of abscess 
formation, we first addressed the effect of intraperitoneal Sp1 challenge on macrophages that 
constitute – as in a septic abscess – a main part of the wall of an experimental abscess.21 
CD11b-positive macrophages migrate into the peritoneal cavity upon Sp1 challenge (Fig. 2a). 
Within 6 h after Sp1 challenge they represent more than 50% of the incoming cells. 
Administration of SCCA alone, as a control, attracts significantly less macrophages and total 
cells into the peritoneum. At 24 h after Sp1 challenge, about 28% of cells attracted into the 
peritoneal cavity are CD11b-positive macrophages (Fig. 2b). Macrophages are known be 
capable of internalizing extracellular antigens by various mechanism, such as, pinocytosis, 
phagocytosis, and endocytosis. Using fluorescent microscopy we studied whether the 
IL-6 in polysaccharide-mediated abscess formation          Meemboor et al. 
 
M
a
n
u
sc
rip
t a
cc
e
pt
e
d 
at
 
In
n
a
te
 
Im
m
u
n
ity
,
 
Au
gu
st
 
20
09
 
 
14 
 
peritoneal macrophages internalize Sp1. Indeed, administration of fluorescent-labelled Sp1 
results in Sp1 internalization by about 90% of peritoneal macrophages (Fig. 2c). We 
investigated whether Sp1 internalization by macrophages leads to IL-6 secretion. Intracellular 
cytokine staining of peritoneal macrophages 6 h after Sp1 challenge demonstrates that almost 
90% of the Sp1-induced peritoneal macrophages show cytoplasmic expression of IL-6 (Fig. 
2d). Macrophages represent the principal constituent of the abscess wall. 
Immunohistochemical analyses of abscesses examined 6 d following Sp1 challenge, 
demonstrate incorporation of IL-6 positive macrophages in the wall (Fig. 2e). Altogether, this 
result demonstrates that IL-6 secreted by macrophages is a predominant cytokine in Sp1-
mediated abscess formation.  
 
Sp1-mediated IL-6 secretion by DCs in vitro 
In an experimental model of abscess formation, besides macrophages, CD11c-positive DCs 
play an important role. They also migrate into the peritoneal cavity upon Sp1 challenge and 
are retrieved from the abscess capsule.10 About 7% of the total cells attracted into the 
peritoneal cavity by Sp1 application are CD11c-positive DCs.10 IL-6-positive DCs are 
incorporated into the abscess wall secrete (Fig. 3a). To gain information about the specificity 
of the Sp1-induced IL-6 synthesis in APCs, we decided to examine the IL-6 secretion by DCs 
in vitro. Bone marrow-derived DCs treated for 33 h with different concentrations of Sp1 in 
vitro secrete IL-6 in a dose-dependent manner (Fig. 3b). As negative controls, medium and 
chemically modified Sp1 were used. Chemical modification by neutralization of the free 
amino group on the 2-acetamido-4-amino-2,4,6-trideoxygalactose by N-acetylation creates a 
polysaccharide with a net negative charge. Medium alone and chemically modified Sp1 failed 
to induce dose-dependent IL-6 secretion by DCs. This result demonstrates that IL-6 secretion 
depends on the zwitterionic charge motif of Sp1. 
IL-6 in polysaccharide-mediated abscess formation          Meemboor et al. 
 
M
a
n
u
sc
rip
t a
cc
e
pt
e
d 
at
 
In
n
a
te
 
Im
m
u
n
ity
,
 
Au
gu
st
 
20
09
 
 
15 
 
 
Sp1-induced peritoneal CD4+ T cell influx depends on IL-6 
Abscess formation depends on CD4+ T migrating into the peritoneal cavity.17 IL-6 has been 
described as a migration factor for CD4+ T cells in different tissues. We measured the CD4+ T 
cell, macrophage and DC cell counts in the peritoneal lavage following Sp1 challenge of 
wildtype mice, IL-6-deficient mice, and IL-6-deficient mice treated intraperitoneally with IL-
6. As controls, cell counts were made from peripheral blood and spleens of wildtype and IL-6-
deficient mice. The CD4+ T cell counts in the spleen and peripheral blood of wildtype and IL-
6-deficient mice were similar (Table 1). However, compared to wildtype mice, the peritoneal 
lavage of IL-6-deficient mice showed a 73% decrease in the CD4+ T cell count. The 
peritoneal macrophage cell count was similar in WT and IL-6-deficient mice. The number of 
DCs was reduced in IL-6-deficient mice when compared to WT mice. Exogenous IL-6 
cytokine treatment of IL-6 KO mice restored the cell count of macrophages, DCs, and CD4+ T 
cells in the peritoneal cavity to levels of WT mice. The results suggest a functional role of IL-
6 as a migration factor for CD4+ T cells into the peritoneum.  
 
Anti-apoptotic effect of Sp1-mediated IL-6 secretion on CD4+ T cells  
Sp1 induces MHC class II- and co-stimulation-dependent CD4+ T cell activation in vitro.8, 18 
IL-6 stimulates the activation, survival, and proliferation of CD4+ T cells, acting on T cells as 
an anti-apoptotic factor.32-35 We therefore tested whether Sp1 supports the survival and 
inhibits apoptosis of CD4+ T cells; and whether the effect requires IL-6. Spleen cells of 
C57/Bl6 wildtype mice were starved and CD4+ T cells were examined for apoptosis in the  
presence and absence of Sp1 and chemically modified Sp1. As a control, CD4+ T cells were 
incubated in non-starving medium. Fluorescence staining of CD4+ cells with the apoptosis 
marker annexin V, revealed that in contrast to medium and modified Sp1, native Sp1 
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decreases apoptosis (16% apoptotic cells versus 39% and 42%) (Fig. 4). At the same time, in 
the presence of Sp1, 15% of CD4+ T cells stained positively with PI, a marker for cell death. 
Thirty-seven % and 42% were stained with PI in the absence of Sp1 and in the presence of 
chemically modified Sp1, respectively. This observation shows an anti-apoptotic effect of Sp1 
on CD4+ T cells. The analysis was applied to spleen cells of IL-6-deficient mice of the 
C57/Bl6 background. IL-6-deficient cells treated with Sp1 did not inhibit apoptosis of CD4+ T 
cells. Sixty-five % of CD4+ T cells stained positively with annexin V. In contrast, 36% and 
42% of cells left untreated, or treated with modified Sp1 as controls were positive for annexin 
V, respectively (Fig. 4). The result correlated with the findings of the PI staining, revealing 
that in the absence of IL-6 the inhibitory effect of Sp1 on cell death was abrogated. Sixty-two 
% of CD4+ T cells were dead in the presence of Sp1. Thirty-one % and 43% of CD4+ T cells 
stained positively for PI when left untreated or treated with modified Sp1, respectively. In 
summary, the anti-apoptotic effect of Sp1 depends on IL-6.  
 
Sp1-induced IL-6 activates IL-17 expression in CD4+ T cells 
In an experimental abscess model with the ZPS PS A1, the induction of abscesses was shown 
to be dependent on IL-17 secreting CD4+ T cells. We first addressed whether the ZPS Sp1 
induced cytoplasmic expression of IL-17 in CD4+ T cells and then analyzed the contribution 
of IL-6 on the IL-17 cytokine expression. Eighteen h after Sp1 challenge, lavage CD4+ T cells 
of wildtype and IL-6-deficient mice were studied by intracellular IL-17 staining. Control mice 
were challenged with SCCA alone. In Figure 5, the results are summarized in a histogram 
overlay. In wildtype mice, 59% of peritoneal CD4+ T cells express cytoplasmic IL-17 upon 
Sp1 challenge. In contrast, in IL-6-deficient mice challenged with Sp1, 6% of peritoneal 
CD4+ T cells express IL-17. Altogether, cytoplasmic expression of IL-17 by CD4+ T cells 
upon Sp1 challenge requires IL-6.   
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The requirement of IL-6 in Sp1-induced abscess formation 
We then tested whether IL-6 is essential for the formation of Sp1-induced abscesses. 
Peritoneal administration of Sp1 to wild type mice produced abscesses (Fig. 6). In contrast, 
abscess formation by Sp1 in IL-6 deficient mice was significantly reduced (p<0.05). SCCA 
alone and challenge with chemically modified Sp1 used as negative controls did not induce 
abscesses (p<0.05). Furthermore, peritoneal administration of an anti-IL-6 neutralizing mAb 
with the intraperitoneal Sp1 challenge and again 6 h later resulted in a 50% reduction of 
abscess formation.  
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DISCUSSION 
In this study, we demonstrate the need of IL-6 for the formation of polysaccharide-mediated 
intraperitoneal abscesses. In contrast to experimental abscess models in rats using whole B. 
fragilis and PS A1 as causative agents, Sp1 challenge in mice induces significantly higher 
levels of IL-6 than IL-1 and TNF-α.19,20 ZPS have in common the zwitterionic charge motif 
that contains at least one positive and one negative charge per repeating unit.5 However, for 
example, PS A1 has exactly one positive charge and one negative charge and Sp1 has two 
negative charges and one positive charge per repeating unit. Also, the saccharides and their 
number per repeating unit differ. Besides the animal species, structural differences might 
explain distinction of the cytokine production. IL-6 has been recognized as a major participant 
in elevating the inflammatory response in inflammatory bowel diseases such as Crohn’s 
disease and ulcerative colitis. Interestingly, in contrast to ulcerative colitis, Crohn’s disease 
which is frequently associated with intraperitoneal sepsis and abscess formation, higher IL-6 
serum concentrations are found.46, 55  
Peritoneal macrophages and DCs, both participating in the organization of the abscess wall, 
secrete IL-6 upon Sp1 treatment. Macrophages are an important cellular element, since they 
are resident in the peritoneal cavity and help initiate immune responses through phagocytosis 
and cytokine secretion.56 DCs that represent a minor population of APCs migrating into the 
peritoneal cavity upon Sp1 challenge, are also incorporated into the abscess wall.10 We show 
in bone marrow-derived DCs in vitro, that the induction of IL-6 clearly depends on the 
zwitterionic charge motif because Sp1 lacking the free amino group and thus resembling a 
common negatively-charged polysaccharide induces a significantly lower IL-6 level.   
In recent years, Toll-like receptors (TLRs), which recognise a variety of pathogen-associated 
molecular patterns of infectious agents, have emerged as critical for this recognition.57 In 
mammalian tissues, TLRs are highly expressed by resident immune cells, including above all 
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DCs and tissue macrophages. Upon binding ligands, all known TLRs except for TLR3 can 
activate downstream signalling cascades through the adaptor protein MyD88 to induce the 
production of inflammatory cytokines. These cytokines are interferon-α (IFN-α), IFN-β, IL-
12, TNF-α, IL-1, and IL-6. In contrast to PS A1 from B. fragilis that causes macrophages and 
DCs to secrete IL-12 and TNF-α in a TLR2-dependent pathway, these APCs neither secrete 
TNF-α nor IL-12 in response to Sp1 (unpublished data).58 Thus, the immune response to the 
ZPS Sp1 with predominant IL-6 secretion might be conferred by another TLR than TLR2. 
The CD40 ligand interaction on T cells with the CD40 on APCs is critical to elevate 
expression of other co-stimulatory molecules and the secretion of a variety of cytokines 
including IL-6.59 It is feasible that the previously published requirement of co-stimulatory 
interactions via B7-CD28 and CD40-CD40L for ZPS-dependent CD4+ T cell activation and 
abscess formation contribute significantly to the up-regulation of IL-6 synthesis.17,18.  
In comparison to WT mice, in IL-6-deficient mice the total number of macrophages and DCs 
is decreased by 28% (33.8% of total cells in WT mice and 24.3% of total cells in IL-6-
deficient mice). However, the number of influx CD4+ T cells is reduced by 73% in the 
peritoneal cavity in IL-6-deficient mice. Besides suggestion a pleiotropic effect of IL-6 on 
antigen presenting cells, the result also identifies IL-6 as a potential CD4+ T cell migration 
factor in the peritoneum. Sp1 induces T cell activation and proliferation of mammalian CD4+ 
T cells in vitro and in vivo.8,10,60 Activation and proliferation of CD4+ T cells is sustained by 
IL-2 secretion. Prevention of apoptosis through IL-6 has been shown in T cells at different 
stages of the cell cycle.35 Testing the effect of Sp1 on apoptosis of CD4+ T cells, we observe 
that Sp1 inhibits their apoptosis. This effect is abrogated when the ZPS is converted into a 
non-ZPS and in the absence of IL-6. This result implies that IL-6 is an essential cofactor for 
the protection from cell death and might indirectly support IL-2-mediated cellular activation 
and proliferation in response to ZPS.61,62 
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Here, we observe intracellular IL-17 expression by peritoneal CD4+ T cells. This observation 
confirms the reported result by Chung et al. who demonstrated IL-17 expression by CD4+ T 
cells in response to whole B. fragilis.22  Interestingly, we did not detect IL-17 in significant 
quantities in the lavage fluid (data not shown) but by intracellular staining. This finding might 
be explained by the low quantity of CD4+ T cells accumulating in the peritoneal cavity 24 h 
after Sp1 challenge which only represent about 1% of the total cells.10 We show here that IL-
17 expression of peritoneal CD4+ T cells in response to the model ZPS Sp1 is IL-6-dependent. 
IL-6 and TGF-β have been identified as differentiation factors for TH17 cells.63,64,65 Presently, 
it is unclear what the physiological conditions are that allow TH17 differentiation despite the 
presence of interference by pre-existing TH1 and TH2 cells. Presumably, APCs ubiquitously 
produce low amounts of TGF-β in response to an activation stimulus, but the local TGF-β 
production at the site of interaction of APCs with naïve T cells seems to be crucial for the 
TH17 development.66,67 Future studies will address the role of TGF-β in ZPS-induced TH17 
cells.   
The crucial question is whether abrogation of the pleiotropic functions of IL-6 blocks abscess 
formation. Indeed, abscess formation is significantly inhibited in IL-6-deficient mice. Various 
options for the prevention and treatment of abscesses are still being investigated. For example, 
in a peritonitis model in rats, treatment with tissue-type plasminogen and urokinase during the 
first 24 h after leakage of intestinal contents into the peritoneal cavity was very effective in 
preventing intra-abdominal abscess formation.68 Besides the prophylaxis and treatment of 
pathologies with anti-IL-6 monoclonal antibodies that has been shown to be effective against 
lethal Escherichia coli infection, lethal TNF-α challenge in mice, and Crohn’s disease, we see  
that treatment of mice with a neutralizing IL-6-specific antibody reduces abscess formation by 
50%.45,69,70 As a consequence, early application of an IL-6-specific antibody, or targeting of 
IL-6 signalling or trans-signalling, in secondary peritonitis or abdominal surgery involving  
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intestinal incisions may offer a prophylactic strategy for the prevention of intra-peritoneal 
abscess formation.45  
Based on these results we conclude that in peritoneal abscess formation induced by the ZPS 
Sp1, macrophages and DCs recognize the ZPS and secrete IL-6 which stimulates the IL-17-
expression of CD4+ T cells and inhibits their apoptosis. Inhibition of abscess formation in the 
absence of IL-6 confirms the biologic importance of this innate immune mediator for the 
cellular adaptive host response.  
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LEGENDS 
 
Fig. 1: Intraperitoneal administration of Sp1 induces peritoneal IL-6. At different time points 
after intraperitoneal Sp1 challenge, peritoneal lavage fluid was analyzed for IL-1, IL-6, and 
TNF-α by a multiplex bead assay. As a control, peritoneal lavage fluid of mice challenged 
with SCC adjuvant alone was taken at different time points, pooled, and analyzed for 
cytokines. The figure shows the result of 3 experiments performed independently each with 4 
mice per group.  
 
Fig. 2: Sp1 induces IL-6 secretion by peritoneal macrophages. a, Influx into the peritoneum, 
of total cells (squares) and CD11b-positive macrophages (triangles) was measured in C57Bl/6 
mice (six per group) challenged with Sp1 (filled symbols) and SCCA controls (open 
symbols). The peritoneal lavage was performed at different time intervals (x-axis) after 
challenge. Cell numbers were determined by cell counting and flow cytometry. Bars indicate 
standard errors within a group tested. b, Twenty-four h after intraperitoneal Sp1 challenge, 
macrophages (Mac) of the peritoneal influx were stained with PE-conjugated anti-CD11b 
mAb and analyzed by flow cytometry. Numbers in the right dot plot represent the percentage 
of positive macrophages, gated as indicated in the left dot plot and non-gated cells, 
respectively. c, Peritoneal macrophages internalize Sp1. Mice were challenged 
intraperitoneally with Sp1-Alexa 594 (100 µg). Twenty-four h after Sp1 challenge, cells of 
the peritoneal influx were stained with FITC-conjugated anti-CD11b and analyzed by 
fluorescent microscopy. Scale bar, 10 µm. d, Six h after intraperitoneal challenge with Sp1 
plus SCC or SCC alone, macrophages (Mac) of the peritoneal influx were surface-stained 
with PE-conjugated anti-CD11b mAb, and intracellularly with FITC-conjugated anti-IL-6, 
then analyzed by flow cytometry. Numbers in the quadrants of the dot blot represent the 
percentage of positive macrophages. e, Six d after Sp1 challenge, cryo-sectioned 
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intraperitoneal abscesses were stained with anti-F4/80 to stain macrophages (brown) and anti-
IL-6 (red), and analyzed by light microscopy (20 x). The left panel shows an overview of a 
partial abscess. The right panel demonstrates the abscess capsule highlightened in the 
rectangular box in the left panel. White arrows indicate double-stained cells, red arrows 
indicate F4/80-positive IL-6-negative cells.   
 
Fig. 3: Effect of Sp1 on IL-6 secretion by DCs. a, Six d after Sp1 challenge, cryo-sectioned 
intraperitoneal abscesses were stained with an CD11c-specific antibody to stain DCs (brown) 
and anti-IL-6 (red), and analyzed by light microscopy (20 x). b, Bone marrow-derived DCs 
were treated in medium alone (empty bar), with chemically modified Sp1 (gray bars) and Sp1 
(black bars), at different concentrations, or LPS as positive control (100 ng/ml) (striped bar) 
for 33 h (x-axis). Supernatants were analyzed for IL-6 by ELISA.  
 
Fig. 4: Sp1 inhibits apoptosis through IL-6. Spleen cells from wildtype mice and IL-6-
deficient mice were treated in starvation medium alone, with chemically modified Sp1 (100 
µg/ml), and Sp1 (100 µg/ml) for 12 h. As a control, cells were incubated in non-starvation 
medium alone. Apoptosis of CD4+ T cells was evaluated by Annexin V staining, cell death by 
PI staining. CD4+ T cells were analyzed by flow cytometry. Numbers above the marker 
represent the percentage of annexin V- or PI-positive CD4+ T cells of total CD4+ T cells. 
Dotted black line, non-starvation medium alone (control); gray line, starvation medium alone; 
dashed gray line, modified Sp1-treated cells; black line, Sp1-treated cells.  
 
Fig. 5: Effect of Sp1-induced Il-6 on IL-17 expression by CD4+ T cells. Twenty-four h after 
intraperitoneal Sp1 challenge (100 µg) or SCCA challenge as a control, the peritoneal lavage 
CD4+ T cells of challenged WT and IL-6-deficient mice were analyzed for intracellular IL-17 
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(x-axis) by flow cytometry. Filled black line, isotype control of CD4+ T cells isolated from 
SCCA-challenged mice; white line, IL-17 of CD4+ T cells isolated from SCCA-challenged 
mice; gray line, isotype control of CD4+ T cells isolated from Sp1-challenged mice; black 
line, IL-17 of CD4+ T cells from Sp1-challenged mice. The figure shows the representative 
result out of 4 experiments performed independently with 3 mice in each group. 
 
Fig. 6: IL-6-dependency of Sp1-mediated T cell-dependent abscess formation. a, C57BL/6 or 
IL-6 -/- mice were challenged intraperitoneally with sterile cecal adjuvant alone (SCCA) and 
modified Sp1 as control, or Sp1 in the presence or absence of anti-IL-6 antibody 
simultaneously applied into the peritoneum. After 6 d intraperitoneal abscess formation was 
examined at autopsy. One dot represents the total abscess diameter per mouse; bars indicate 
the median abscess size per group. 
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Table 1: T cell counts in C57BL/6 wildtype and IL-6-deficient mice. C57BL/6 WT and IL6-/- 
mice were challenged intraperitoneally with Sp1 (100 µg) plus SCC (5 mice per group). One 
group of IL-6-/- mice were treated intraperitoneally with mouse IL-6 (100 µg/kg) at the time of 
challenge, and at 6 h and 12 h following Sp1 challenge. Twenty-four h after challenge, cells 
from C57BL/6 WT and IL6-/- mice were isolated from the peritoneum by lavage, and from 
blood and spleen, stained with anti-CD4, and analyzed by flow cytometry. In addition, 
peritoneal lavage cells were stained with anti-CD11b and anti-CD11c antibodies to stain 
macrophages and DCs, respectively. Numbers represent the percentage of cells of the total 
cells or the absolute number. 
 
 Blood Spleen  Peritoneum   
  [%] [%]   [%]  [%]  [%]  [cells x103/ml] 
  CD4 CD4 Mac DC CD4 CD4 
Wildtype        33.6±2.0 21.2±5.8   26.5±13.9 7.3±0.7 4.1±0.4 39.3±3.5 
IL6-/-                35.2± 3.0 18.8±5.9 22.6±5.3 1.7±1.1 1.1±0.1   9.5±0.7 
IL6-/- (+IL6) n.d. n.d.   28.1±10.1 6.1±2.4 4.3±0.1      41.2±4.0   
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Intraperitoneal administration of Sp1 induces peritoneal IL-6. 
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Sp1 induces IL-6 secretion by peritoneal macrophages. 
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Effect of Sp1 on IL-6 secretion by DCs. 
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Sp1 inhibits apoptosis through IL-6. 
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Effect of Sp1-induced IL-6 secretion on TH17 polarization. 
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IL-6-dependency of Sp1-mediated T cell-dependent abscess formation. 
 
